Location, study period (reference)	PM size	Type of fuel	Mean (μg/m3)	Notes

China

Shenyang, China, May 2006 (this study)	PM10	Crop residue	Total: 100.6Cooking times: 202.1	Based on ~14 hr/day (0530–1930) for 5 consecutive days3 households

Jilan, China, Nov–Dec 2001, Feb–Mar 2003, 2004 (Fischer and Koshland 2007)	PM4	Multiple fuels: coal, biomass, gas, electricity	Daily average: 3121-hr peak: 1,880	Based on 24-hr periods and 1-hr peak values70 household-days37 households

Gansu, China, Mar–Apr 2003, Dec 2003–Jan 2004 (Jin et al. 2005)	PM4	Wood and crop residue	Mar–Apr 2003: 518Dec 2003–Jan 2004: 661	Based on 24-hr/day periodsMar–Apr 2003: 72 households with 1 day of measurement, 6 households with 4 days of measurementDec 2003–Jan 2004: 17 households with 1 day of measurement, 6 households with 2–3 days of measurement

Guizhou, China, Mar–Apr 2003, Dec 2003–Jan 2004 (Jin et al. 2005)	PM4	Coal, wood, and crop residue	Mar–Apr 2003: 352Dec 2003–Jan 2004: 301	Based on 24-hr/day periodsMar–Apr 2003: 76 households with 1 day of measurement, 7 households with 2–4 days of measurementDec 2003–Jan 2004: 16 households with 1 day of measurement, 6 households with 2–3 days of measurement

Inner Mongolia, China, Dec 2003–Jan 2004 (Jin et al. 2005)	PM4	Wood and crop residue	718	Based on 24-hr/day periods49 households with 1 day of measurement, 4 households with 3 days of measurement

Shaanxi, China, Mar–Apr 2003, Dec 2003–Jan 2004 (Jin et al. 2005)	PM4	50% coal, 50% wood and crop residue	Mar–Apr 2003: 187Dec 2003–Jan 2004: 223	Based on 24-hr/day periodsMar–Apr 2003: 75 households with 1 day of measurement, 6 households with 4 days of measurementDec 2003–Jan 2004: 18 households with 1 day of measurement, 6 households with 3 days of measurement

Guizhou, China, Jan 2003 (He et al. 2005)	PM4	Coal (3 households), coal and biomass (1 household)	1,944	Based on 24-hr/day periods for 4 consecutive days4 households

Shaanxi, China, Feb 2003 (He et al. 2005)	PM4	Coal and biomass for cooking, coal for heating	205	Based on 24-hr/day periods for 4 consecutive days4 households

Zhejiang, Hubei, and Shaanxi, China, Jun–Aug 2002, Dec 2002–Jan 2003 (Edwards et al. 2007)	PM4	Crop residues	Summer: 282.9Winter: 456.4	Based on 24-hr periods48 households for summer, 25 for winter

Bolivia

Cantuyo, Jan 1994–Oct 1995 (Albalak et al. 1999)	PM10	Dung	1,830	Based on 6-hr periods (0500–1100)/day every 6 days for 3 consecutive weeks for each month of study period12 households

India

Pauri District, Garhwal Himalaya, northern India, Aug 1989–Jul 1990 (Saksena et al. 1992)	TSP	Wood	Cooking times: 5,600Noncooking times: 820	Based on 15-hr periods12 households

Tamil Nadu, southern India, Jul–Dec 1999 (Balakrishnan et al. 2002)	PM4	Wood and crop residue	Indoor kitchen without partitions: 1,442Kitchen with partitions: 970	Based on 10- to 12-hr/day periods for 1–3 daysWithout partitions: 105 householdsWith partitions: 68 households

Andhra Pradesh, southern India, Jan–May 2001 (Balakrishnan et al. 2004)	PM4	WoodDung	Wood: 500Dung: 732	Based on 22- to 24-hr/day sampling periods for 3–4 daysWood: 270 householdsDung: 97 households

Guatemala

Quetzaltenango, May–Nov 1993 (Naeher et al. 2000)	PM2.5PM10TSP	Wood	PM2.5: 527.9,a 96.5bPM10: 717.1,a 186.3bTSP: 835.8,a 275.5b	Based on three 22-hr sampling periods3 households

La Victoria, Jan 1999 (Bruce et al. 2004)	PM3.5	Wood and crop residue	1,019a351b	Based on one 24-hr measurement/ household11 households with open fires, 5 with planchas

La Victoria, Dec 1998–Jul 1999 (Albalak et al. 2001)	PM3.5	Wood	1,560a280b	Based on 24-hr measurements taken 6 times at 1-month intervals10 households of each stove type

Location, study period (reference)	PM size	Type of fuel	Mean (μg/m3)	Notes

Cantuyo, Jan 1994–Oct 1995 (Albalak et al. 1999)	PM10	Dung	1,830	Based on 6-hr periods (0500–1100)/day every 6 days for 3 consecutive weeks for each month of study period12 households

India

Pauri District, Garhwal Himalaya, northern India, Aug 1989–Jul 1990 (Saksena et al. 1992)	TSP	Wood	Cooking times: 5,600Noncooking times: 820	Based on 15-hr periods12 households

Tamil Nadu, southern India, Jul–Dec 1999 (Balakrishnan et al. 2002)	PM4	Wood and crop residue	Indoor kitchen without partitions: 1,442Kitchen with partitions: 970	Based on 10- to 12-hr/day periods for 1–3 daysWithout partitions: 105 householdsWith partitions: 68 households

Andhra Pradesh, southern India, Jan–May 2001 (Balakrishnan et al. 2004)	PM4	WoodDung	Wood: 500Dung: 732	Based on 22- to 24-hr/day sampling periods for 3–4 daysWood: 270 householdsDung: 97 households

Guatemala

Quetzaltenango, May–Nov 1993 (Naeher et al. 2000)	PM2.5PM10TSP	Wood	PM2.5: 527.9,a 96.5bPM10: 717.1,a 186.3bTSP: 835.8,a 275.5b	Based on three 22-hr sampling periods3 households

La Victoria, Jan 1999 (Bruce et al. 2004)	PM3.5	Wood and crop residue	1,019a351b	Based on one 24-hr measurement/ household11 households with open fires, 5 with planchas

La Victoria, Dec 1998–Jul 1999 (Albalak et al. 2001)	PM3.5	Wood	1,560a280b	Based on 24-hr measurements taken 6 times at 1-month intervals10 households of each stove type


	Coefficient	Standard error	P	Adjusted R2

Overall survival

Sampling time	0.2797	0.1995	0.18	4.16%

Metastatic status	−0.0362	0.1089	0.744	−11.16%

Sample size	−0.0006	0.0006	0.401	2.35%

Cut-off value	0.0020	0.0016	0.229	23.59%


AGI	Annotation	P-score	References

AT2G30870	ERD13, glutathione-S-transferase PHI 10	32	Ryu et al. (2009), Carter et al. (2004) and Marmagne et al. (2007)

AT2G45820*	Remorin, putative DNA-binding protein, salt-induced	22	Benschop et al. (2007), Nelson et al. (2006) and Kreps et al. (2002)

AT1G04690	KAB1, KV-BETA1 (potassium channel beta subunit)	18	Maathuis (2006)

AT3G18240*	Unknown protein, phosphorylated	18	de la Fuente van Bentem et al. (2008)

AT1G53070*	Legume lectin family protein, cell wall asscociated	15

AT1G09210*	CRT2, Calreticulin 2; calcium ion binding	13	Jiang et al. (2007)

AT1G56340*	CRT1, Calreticulin 1; calcium ion binding	12	Jiang et al. (2007)

AT5G38480*	GRF3, 14-3-3 PSI, overexpression confers salt tolerance	9	Marmagne et al. (2007) and Du et al. (2008)

AT3G02750*	PP2C, protein phosphatase 2C family, group E	9	Bassel et al. (2008)

AT5G19440	CAD, Cinnamyl-alcohol dehydrogenase, putative	9	Marmagne et al. (2007)

AT3G18820	RAB71, (Arabidopsis RAB GTPase homolog G3F); GTP binding	8	Marmagne et al. (2007)

AT2G02990	RNS1, (Ribonuclease 1); cell wall/plasma membrane associated	8

AT1G02090*	CSN7, MAP kinase kinase; subunit of COP9 signalosome	7

AT5G16050*	GRF5, 14-3-3 UPSILON (general regularory factor 5)	6	Marmagne et al. (2007)

AT2G43940	Thiol methyltransferase, putative, chloroplast envelope	6

AT5G07340	Calnexin, putative, vacuolar	6	Schmidt et al. (2007)

AT1G28200	FIP1 (FH interacting protein 1), VirF-interacting protein FIP1	5

AT1G78300	GRF2, 14-3-3 OMEGA, (general regularory factor 2)	5	Chang et al. (2009)

AT3G06300	P4H-2, (prolyl-4-hydroxylase, isoform 2); endomembrane system	5

AT1G77120*	ADH1, (alcohol dehdrogenase 1); salt stress-responsive	5	de la Fuente van Bentem et al. (2008) and Jiang et al. (2007)

AT5G67500	VDAC2 (voltage-dependent anion channel 2), seedling development	5	Yan et al. (2009) and Lee et al. (2009)

AT3G01280	VDAC1 (voltage-dependent anion channel 1)	5	Lee et al. (2009)

AT1G74020	SS2 (STRICTOSIDINE SYNTHASE 2); strictosidine synthase	5	Marmagne et al. (2007)

AT4G17720*	RNA recognition motif (RRM)-containing protein, phosphorylated	5	de la Fuente van Bentem et al. (2006)

AT4G18800	RABA1D (Arabidopsis RAB GTPase homolog A1D);	5	Marmagne et al. (2004)

AT3G61990	O-methyltransferase family 3 protein, cytosolic	4

AT1G22280*	PAPP2C, phytochrome-associated protein phosphatase 2C; group F	4	de la Fuente van Bentem et al. (2008) and Phee et al. (2008)

AT3G15260*	PP2C, protein phosphatase 2C family, group F	4

AGI	Annotation	P-score

AT3G15260*	PP2C, protein phosphatase 2C family, group F	4


VARIABLE, n (%)

Age, mean (Years)

Gender

Male

Female

Race

Blacks

Whites

Education

≤ High or trade

Some College

College degree

≥ Graduate School

Income (Self) mean (past 12 months)

< $10 K (1)

$11–20 K (2)

$21–30 K (3)

$31–50 K (4)

$51–75 K (5)

$76–100 K (6)

> $101 K (7)


Variable	OR	p	95% conf. interval

Received blood transfusion

Age	1.12	<0.01	1.06–1.19

Sex	1.35	0.32	0.74–2.46

Bilirubin	0.81	0.01	0.69–0.95

No blood transfusion

Age	1.01	0.85	0.94–1.07

Sex	1.80	0.06	0.98–3.29

Bilirubin	0.86	0.20	0.69–1.08


	Placebo(n = 6)

Male/Female (numbers)	2/4

Age (years)b	16 (13-24)

Median nerve MNCV (m/s)a	17.9 (6.0)

Median nerve minimal F response latency (ms)a	83.8 (28.0)*

CMAP amplitude abductor pollicis brevis muscle (mV)a	3.9 (1.1)

Three point grip (N)a	50.9 (14.4)

Foot dorsiflexors (N)a	79.5 (14.0)

ISSb	2 (0-8)

CMTNSb	10 (7-20)

ODSSb	3 (2-4)

ALDSa	86.8 (6.5)

Nine hole peg test (s)a	26.3 (6.6)

50 m walking (s)a	31.9 (2.0)


Treatment	Vehicle control	Positive control MMC(0.20 μg/mL)	NR-INF-02(2500.00 μg/mL)	NR-INF-02(791.14 μg/mL)	NR-INF-02(250.36 μg/mL)

R1	R2	R1	R2	R1	R2	R1	R2	R1	R2

Total number of metaphase analyzed	100	100	100	100	100	100	100	100	100	100

Normal	99	100	92	92	98	97	98	96	98	100

Chromatid break	1	—	—	4	1	—	1	—	—	—

Chromosome break	—	—	—	1	—	1	—	—	—	—

Deletion	—	—	—	1	—	—	—	—	1	—

Ring	—	—	3	1	1	—	—	—	1	—

Dicentric	—	—	5	1	—	2	—	1	—	—

Fragment	—	—	—	—	—	—	—	1	—	—

Gap	—	—	—	—	—	—	1	1	—	—

Ploidy	—	—	—	—	—	—	—	1	—	—

Endoreduplication	—	—	—	—	—	—	—	—	—	—

Total aberrations	1	0	8	8	2	3	1	1	2	0

Total aberrations (Mean ± SD)	0.50 ± 0.70	8.00 ± 0.00*	2.50 ± 0.70	1.0 ± 0.00	1.00 ± 1.41

Mitotic Index (Mean ± SD)	5.35 ± 0.49	2.63 ± 0.10*	3.75 ± 1.06	4.25 ± 0.35	4.0 ± 0.42

Treatment	Vehicle control	Positive control MMC(0.20 μg/mL)	NR-INF-02(2500.00 μg/mL)	NR-INF-02(791.14 μg/mL)	NR-INF-02(250.36 μg/mL)

R1	R2	R1	R2	R1	R2	R1	R2	R1	R2

Endoreduplication	—	—	—	—	—	—	—	—	—	—

Total aberrations	1	0	8	8	2	3	1	1	2	0

Total aberrations (Mean ± SD)	0.50 ± 0.70	8.00 ± 0.00*	2.50 ± 0.70	1.0 ± 0.00	1.00 ± 1.41

Mitotic Index (Mean ± SD)	5.35 ± 0.49	2.63 ± 0.10*	3.75 ± 1.06	4.25 ± 0.35	4.0 ± 0.42


Protein Name	Uniprot ID	Function	Up- or downregulateda

DNA-dependent protein kinase catalytic subunit	P78527	Serine/threonine-protein kinase, molecular sensor for DNA damage.	Up

Lumican	P51884	Collagen fibril organization, epithelial cell migration and tissue repair.	Down

Tetranectin	P05452	Binds plasminogen and isolated kringle 4. Packaging molecules for exocytosis.	Down

Gelsolin	P06396	Key regulator of actin filament assembly and disassembly.	Down

Cartilage acidic protein 1	Q9NQ79	Upregulated by BMP4 in mesenchymal stem cells undergoing chondrogenic differentiation.	Down

Matrin-3	P43243	Transcription and interaction with other nuclear matrix proteins to form the internal fibrogranular network.	N/A

Glucose-6-phosphate isomerase	P06744	Glycolytic enzyme and angiogenic factor (AMF) that stimulates endothelial cell motility.	N/A

Coactosin-like protein	Q14019	Binds to F-actin in a calcium-independent manner.	N/A

Peptidyl-prolyl cis-trans isomerase A	P62937	Accelerates the folding of proteins.	N/A

Myeloperoxidase	P05164	Produces hypochlorous acid (HOCl) used by the neutrophils to kill bacteria and other pathogens.	N/A

Golgin subfamily B member 1	Q14789	Forms intercisternal cross-bridges of the Golgi complex.	N/A

2′-deoxynucleoside 5′-phosphate N-hydrolase 1	O43598	Catalyses cleavage of the N-glycosidic bond of deoxyribonucleoside 5′-monophosphates.	N/A

Protein Name

DNA-dependent protein kinase catalytic subunit

Lumican

Tetranectin

Gelsolin

Cartilage acidic protein 1

Matrin-3

Glucose-6-phosphate isomerase

Coactosin-like protein

Peptidyl-prolyl cis-trans isomerase A

Myeloperoxidase

Golgin subfamily B member 1

2′-deoxynucleoside 5′-phosphate N-hydrolase 1

Uniprot ID	Function	Up- or downregulateda

P78527	Serine/threonine-protein kinase, molecular sensor for DNA damage.	Up

P51884	Collagen fibril organization, epithelial cell migration and tissue repair.	Down

P05452	Binds plasminogen and isolated kringle 4. Packaging molecules for exocytosis.	Down

P06396	Key regulator of actin filament assembly and disassembly.	Down

Q9NQ79	Upregulated by BMP4 in mesenchymal stem cells undergoing chondrogenic differentiation.	Down

P43243	Transcription and interaction with other nuclear matrix proteins to form the internal fibrogranular network.	N/A

P06744	Glycolytic enzyme and angiogenic factor (AMF) that stimulates endothelial cell motility.	N/A

Q14019	Binds to F-actin in a calcium-independent manner.	N/A

P62937	Accelerates the folding of proteins.	N/A

P05164	Produces hypochlorous acid (HOCl) used by the neutrophils to kill bacteria and other pathogens.	N/A

Q14789	Forms intercisternal cross-bridges of the Golgi complex.	N/A

O43598	Catalyses cleavage of the N-glycosidic bond of deoxyribonucleoside 5′-monophosphates.	N/A


 	Group P (n = 13)	Group R(n = 28)	P value

Mean decrease in Hb† (g/dL ± SD‡)	0.21 ± 0.66	0.37 ± 0.67	0.55

Mean procedure time (min ± SD)	87.5 ± 51.3	99.5 ± 46.1	0.28

Incidence of perforation, % (n)	0.0 (0)	3.6 (1)	0.49

Incidence of clip use, % (n)	38.5 (5)	57.1 (16)	0.27

Incidence of muscle injury, % (n)	15.4 (2)	28.6 (8)	0.36

Incidence of postoperative fever, % (n)	7.7 (1)	10.7 (3)	0.76

Incidence of postoperative bleeding, % (n)	0.0 (0)	3.6 (1)	0.49

Percentage of patients who resumed eating on the day after ESD, % (n)	76.9 (10)	82.1 (23)	0.81

	Group P (n = 13)	Group R(n = 28)	P value

Incidence of muscle injury, % (n)	15.4 (2)	28.6 (8)	0.36

Incidence of postoperative fever, % (n)	7.7 (1)	10.7 (3)	0.76

Incidence of postoperative bleeding, % (n)	0.0 (0)	3.6 (1)	0.49

Percentage of patients who resumed eating on the day after ESD, % (n)	76.9 (10)	82.1 (23)	0.81


Material	Thermal conductivity	Specific heat	Density	Electrical conductivity

k(W/m⋅K)	c(J/kg⋅K)	ρ(kg/m3)	σ(S/m)

Plastic	0.026	1045	70	10-5

Electrode	70	840	6450	108

Saline	0.58	3200	1004	a(3)

Hepatic tissue	0.502	3455 (1)	1080 (1)	b(3)

2155 (2)	370.44 (2)

Material	Thermal conductivity	Specific heat	Density	Electrical conductivity

k(W/m⋅K)	c(J/kg⋅K)	ρ(kg/m3)	σ(S/m)

Electrode	70	840	6450	108

Saline	0.58	3200	1004	a(3)

Hepatic tissue	0.502	3455 (1)	1080 (1)	b(3)

2155 (2)	370.44 (2)


Variable	Simple myopia	P value	Astigmatism	P value	ANOVA (four groups)

MMC	No MMC	Paired t-test	MMC	No MMC	Paired t-test

UC	0 ±	0.1 ± 0	P = 0.1	0.04 ± 		P = 0	0


	Mean genome size (1C; pg)

	*R1	*R2	*R3	Mean ± SD

Lestrimellita sp (diploid males)	0.460	0.465	0.465	0.463 ± 0.003

Lestrimellita sp (females)	0.455	0.465	0.470	0.463 ± 0.008


	E-KNG	Q-KNG	Q-TSR	E-TSR

Number of values	105	105	105	105


Gestational age	n	Colonization with enterococci	Colonization with multidrug-resistant enterococci	% multidrug-resistant enterococci

All patients	274	63 (22.9%)	36 (13.1%)	57.1%

≥ 37 weeks of gestation	117	24 (20.5%)	10 (8.5%)	41.7%

32 – 36 weeks of gestation	94	18 (19.1%)	7 (7.4%)	38.9%

< 32 weeks of gestation	63	21 (33.3%)	19 (30.2%)	90.5%


Dimensions of KCSE scale	n	Score range	Mean (SD)	No of items	Cron-bach’s alpha	Item-total correlation r > 0.20	Inter-item correlations r > 0.20 & r < 0.70

Attitude	174	2.8–4	3.6 (0.27)	9	0.63	8/9, 89%	12/36, 33%


	1.5 T	3 T

Number	9	10

Male;Female	3:6	4:6


Characteristic	Partial helmet law	Universal helmet law	P-value*

Number of motorcycle operators	N = 28,207	N = 45,552

Helmet used	42 %	88 %	<0.01

Age (Median)	37	36	0.52

Male	93 %	93 %	0.77

Single Vehicle Crash	39 %	45 %	<0.01

Crash at Intersection	36 %	40 %	<0.01

Night time	18 %	17 %	<0.01

Speed relateda	10 %	17 %	<0.01

Suspicion of alcohol or drugsa	9 %	5 %	<0.01

Rural locationa	17 %	31 %	<0.01

Poor Surface Conditions	6 %	7 %	<0.01

Crash record linked to a medical record	55 %	58 %	<0.01

Died at the scene	3 %	3 %	0.62


Reference	Basin	Number of sequences	Number of species	Intraspecific distance (%)	Intrageneric distance (%)

Pugedo et al., 2016	Jequitinhonha	260	52	0-11.43 (0.44)	1.09-21.55 (12.16)

Nascimento et al., 2016	Itapecuru	440	64	0-8.9 (0.80)	2.65-7.70 (5.13)


Practitioners	Patients

1) Theoretical Stance	1) Reasons for Therapy

A) Integrity of Self	A) specific, individual reason based on symptoms, illness, or sense of dis-ease

B) Human Capacity for Embodiment	B) motivational drive to seek new resources for active coping

C) Central Role Of Embodiment And Integrity Of Self To The Practice

2) The Practice	2) Engagement in the practice and what happens from the patients' point of view

A) Breath and Breathing	A) Process

B) Repetition and Training	B) Shift in Awareness

	a) Negative Emotion

	b) Body Sensation

C) Noticing/Discriminating/Discerning	C) Engagement in

	a) Self Regulation

	b) Self Care

D) Goal of Practice: Integration of Mind, Body and Life Context	D) Integration of Mind, Body and Life Context

	a)Context

	b) Mind-Body Integration

Practitioners	Patients

	b) Body Sensation

C) Noticing/Discriminating/Discerning	C) Engagement in

	a) Self Regulation

	b) Self Care

D) Goal of Practice: Integration of Mind, Body and Life Context	D) Integration of Mind, Body and Life Context

	a)Context

	b) Mind-Body Integration


Characteristics	No (%)

<underline>Age (years)</underline>

20–24	9 (27.3)

25–34	9 (27.3)

35–49	12 (36.3)

>50	3 (9.1)

<underline>No. of years working as applicator</underline>

2 to 5	16 (48.5)

6 to 9	4 (12.1)

10 to 20	10 (30.3)

>20	3 (9.1)

<underline>Protective measure in use</underline>

Boots	8 (24)

Apron	1 (3)

Mask	2 (3)

Gloves	0 (0)

Glasses	2 (6)

Respirator	2 (6)

Plastic for the back	15 (46)

Waterproof garment	1 (3)

Characteristics	No (%)

6 to 9	4 (12.1)

10 to 20	10 (30.3)

>20	3 (9.1)

Protective measure in use

Boots	8 (24)

Apron	1 (3)

Mask	2 (3)

Gloves	0 (0)

Glasses	2 (6)

Respirator	2 (6)

Plastic for the back	15 (46)

Waterproof garment	1 (3)


Period	Ticks collected	Animals inspected	Infestation rate (%)

May-June (2014)	600	87	71

July-August	370	77	69

September-October	231	77	58

November-December	201	47	60

January-February (2015)	159	55	49

March-April	377	75	64

Total (over year)	1,938	418	63

Period	Ticks collected	Animals inspected	Infestation rate (%)

November-December	201	47	60

January-February (2015)	159	55	49

March-April	377	75	64

Total (over year)	1,938	418	63


Scheme sponsorship	State	Recruitment method	Code

Private	Victoria	Direct contact with researcher	E1

Private	Victoria	Scheme	E2

Private	Victoria	Scheme	E3

Private	Victoria	Scheme	E4

Private	Victoria	Scheme	E5

Private	Victoria	Scheme	E6

Private	Queensland	Scheme	E7

Private	Queensland	Scheme	E8

Private	Queensland	Scheme	E9

Not-for-profit	Victoria	Direct contact with researcher	E10

Not-for-profit	Victoria	Scheme	E11

Not-for-profit	Victoria	Scheme	E12

Not-for-profit	Victoria	Scheme	E13

Not-for-profit	Victoria	Scheme	E14

Not-for-profit	Victoria	Scheme	E15

Not-for-profit	Queensland	Direct contact with researcher	E16

Scheme sponsorship	State	Recruitment method	Code

Private	Victoria	Direct contact with researcher	E1

Private	Victoria	Scheme	E2

Privat	Vi	S

Scheme sponsorship	State	Recruitment method	Code

e	ctoria	cheme	E3

Private	Victoria	Scheme	E4

Private	Victoria	Scheme	E5

Private	Victoria	Scheme	E6

Private	Queensland	Scheme	E7

Private	Queensland	Scheme	E8

Private	Queensland	Scheme	E9

Not-for-profit	Victoria	Direct contact with researcher	E10

Not-for-profit	Victoria	Scheme	E11

Not-for-profit	Victoria	Scheme	E12

Not-for-profit	Victoria	Scheme	E13

Not-for-profit	Victoria	Scheme	E14

Not-for-profit	Victoria	Scheme	E15

Not-for-profit	Queensland	Direct contact with researcher	E16


	<underline>Model</underline>	<underline>Terms</underline>

<underline>Overall</underline><underline>Accuracy</underline>	R2 =	p <		Tones	Clicks	Gabors	Music

Language ~ Tones + Clicks + Gabors	0.671	0.001	β =	0.495	0.505	0.054	−

			p =	0.054	0.155	0.786	−

Language ~ Tones + Clicks + Gabors + Music	0.919	6×10-7	β =	0.181	0.261	-0.023	0.655

			p =	0.191	0.165	0.822	3×10-5

<underline>Sensitivity</underline><underline>(</underline><underline>A</underline>'<underline>)</underline>

Language ~ Tones + Clicks + Gabors	0.646	0.002	β =	0.302	0.435	0.229	−

			p =	0.139	0.119	0.323	−

Language ~ Tones + Clicks + Gabors + Music	0.923	5×10-7	β =	0.065	0.273	0.071	0.696

			p =	0.525	0.055	0.533	2×10-5

<underline>Threshold</underline>

Language ~ Tones + Clicks + Gabors	0.606	0.004	β =	0.636	0.520	0.090	−

			p =	0.068	0.030	0.706	−

Language ~ Tones + Clicks + Gabors + Music	0.846	4×10-5	β =	0.287	0.092	0.009	0.599

			p =	0.220	0.595	0.956	6×10-4


Connection Resiliency	Self-Powered WSN	MEDiSN

Failure Sequences	Elapsed Time (s)	Failure Sequences	Elapsed Time (s)

1	24	1500	18	600

2	552	9720	306	2160

3	12,144	32,580	4896	2820

Connection Resiliency	Self-Powered WSN	MEDiSN

Failure Sequences	Elapsed Time (s)	Failure Sequences

1	24	1500	18

2	552	9720	306

3	12,144	32,580	4896

MEDiSN

Elapsed Time (s)

600

2160

2820


Subscale/Criterion	Factor

	1	2	3

SAWS critical life experience	0.047	0.702	0.220

SAWS emotional regulation	0.165	0.869	−0.007

SAWS reminiscence and reflectiveness	0.119	0.814	−0.230

SAWS openness	0.115	0.410	0.682

SAWS humor	0.174	0.589	0.277

ASTI	0.303	0.580	0.565

3D-WS reflective dimension	0.218	−0.022	0.782

3D-WS affective dimension	−0.016	0.202	0.833

3D-WS cognitive dimension	0.372	−0.205	0.753

BWP uncertainty	0.711	0.209	−0.123

BWP value relativism	0.758	0.052	0.127

BWP contextualism	0.850	0.149	0.104

BWP factual knowledge	0.865	0.093	0.268

BWP procedural knowledge	0.743	0.133	0.408

Subscale/Criterion	Factor

	1

SAWS critical life experience	0.047

SAWS emotional regulation	0.165

SAWS reminiscence and reflectiveness	0.119

SAWS openness	0.115

SAWS humor	0.174

ASTI	0.303

3D-WS reflective dimension	0.218

3D-WS affective dimension	−0.016

3D-WS cognitive dimension	0.372

BWP uncertainty	0.711

BWP value relativism	0.758

BWP contextualism	0.850

BWP factual knowledge	0.865

BWP procedural knowledge	0.743


Wound Infections	Non-Wound Infections

Cellulitis/Abscess (11/31)	Seromas (20/31)

Pre-Operative Prophylactic Antibiotics

Cefazolin 8/11 (73%)	Cefazolin 16/20 (80%)

Clindamycin 1/11 (9%)	Clindamycin 3/20 (15%)

Vancomycin 1/11 (9%) (plus gentamicin)	Vancomycin 0/20 (0%)

Unknown 1/11 (9%)	Unknown 1/20 (5%)

The Relationship between Pre-Operative Antibiotics and Post-Operative Wound Cultures

Cefazolin (8/11)	Cefazolin

associated isolates *:	associated isolates *:

MSSA = 3	CoNS = 6

MRSA = 2	MSSA = 1

M. fortuitum = 1	VSE = 1

Unknown = 2	E. coli = 2

Clindamycin	Proteus sp. = 1

associated isolates:	Unknown = 2

E. coli = 7	Culture negative = 7

Vancomycin (1/11) (plus gentamicin)	Clindamycin

associated isolates:	associated isolates:

K. pneumoniae = 2	CoNS = 2

	Culture negative = 2

Wound Infections	Non-Wound Infections

Cellulitis/Abscess (11/31)	Seromas (20/31)

MSSA = 3	CoNS = 6

MRSA = 2	MSSA = 1

M. fortuitum = 1	VSE = 1

Unknown = 2	E. coli = 2

Clindamycin	Proteus sp. = 1

associated isolates:	Unknown = 2

E. coli = 7	Culture negative = 7

Vancomycin (1/11) (plus gentamicin)	Clindamycin

associated isolates:	associated isolates:

K. pneumoniae = 2	CoNS = 2

	Culture negative = 2


	CYP transcripts of O. sanctum	CYP transcripts of O. basilicum	Functions

Arabidopsisannotation	Lamiaceae annotation	Arabidopsisannotation	Lamiaceae annotation

CYP72A14	2	-	8	-	Phenylpropanoid Metabolism

CYP73A1	5	7	23	33	Cinnamate 4-hydroxylase (C4H)

CYP75B1	8	-	8	-	Flavonoid biosynthesis

CYP81D1	2	-	16	-	Phenylpropanoid Metabolism

CYP81F3	1	-	9	-	Phenylpropanoid Metabolism

CYP84A1	2	-	1	-	Coniferaldehyde 5-hydroxylase

CYP93D1	-	-	1	-	Phenylpropanoid Metabolism

CYP98A3	12	-	25	-	4-Coumaryl shikimic/quinic ester 3′-hydroxylase.

CYP98A14	-	16	-	46	p-Coumaryl shikimate hydroxylase

CYP707A2	5	-	4	-	Phenylpropanoid Metabolism (abscisic acid 8′-hydroxylase)

CYP707A3	12	-	13	-	Secondary metabolism (abscisic acid 8′-hydroxylase)

CYP710A1	3	-	7	-	Phenylpropanoid Metabolism

CYP711A1	1	-	1	-	Core phenylpropanoid metabolism

CYP712A1	-	-	2	-	Stilbene, coumarine and lignin biosynthesis


Similarity searches	Common molecules	Common scaffolds

	SF	GF	SF

1	3705	7759	1821

5	473	469	277

10	107	81	69

15	37	23	25

20	20	18	12

25	24	1	8

Common scaffolds

GF

3771

290

51

15

9

1


i) 7 weeks old

 	 	+/+	m1/+	m1/m1

No. of transplantation	9	24	10

Tumor developed	9	24	4

Dead or degrading	0	0	6*

<underline>Tumor size</underline>

large (1.0 - 2.0 cm)	8	24	0

middle (0.5 - 1.0 cm)	1	0	0

small (< 0.5 cm)	0	0	4

<underline>Differentiation</underline>

Ectoderm	9	24	4

Mesoderm	8	21	0

Endoderm	4	14	2

ii) 1 week old

 	 	+/+	m1/+	m1/m1

No. of transplantation	3	8	5

Tumor developed	3	7	5

Dead or degrading	0	1	0

<underline>Tumor size</underline>

large (1.0 - 2.0 cm)	0	0	0

middle (0.5 - 1.0 cm)	2	5	0

small (< 0.5 cm)	1	2	5

<underline>Differentiation</underline>

Ectoderm	3	7	0

Mesoderm	2	5	0

Endoderm	2	4	0

i) 7 weeks old

		+/+	m1/+	m1/m1

No. of transplantation	9	24	10

Tumor developed	9	24	4

Dead or degrading	0	0	6*

Tumor size

large (1.0 - 2.0 cm)	8	24	0

middle (0.5 - 1.0 cm)	1	0	0

small (< 0.5 cm)	0	0	4

Differentiation

Ectoderm	9	24	4

Mesoderm	8	21	0

Endoderm	4	14	2

ii) 1 week old

		+/+	m1/+	m1/m1

No. of transplantation	3	8	5

Tumor developed	3	7	5

Dead or degrading	0	1	0

Tumor size

large (1.0 - 2.0 cm)	0	0	0

middle (0.5 - 1.0 cm)	2	5	0

small (< 0.5 cm)	1	2	5

Differentiation

Ectoderm	3	7	0

Mesoderm	2	5	0

Endoderm	2	4	0


Organism	Common name	Group	Annotation status

Acanthamoeba castellanii	Amoeba	BCM-HGSCa	Server set up in progress

Helicoverpa armigera	Cotton bollworm	CSIROb	Server set up and analysis in progress

Pythium ultimum	Pythium blight	GMOD	Used one contig to teach a GMOD course

Zea maize	Corn	Iowac	Server set up in progress

Manduca sexta	Goliath moth	Kansasd	Server set up in progress

Mayetiola destructor	Hessian fly	Kansas	Server set up and analysis in progress

Acromyrmex echinatior	Leaf cutting ant	Missouri

Apis mellifera	Honey bee	LBNL/Missouri	Server is available for ongoing annotation

Atta cephalotes	Leaf cutting ant	Missouri

Bombus impatiens	Eastern bumble bee	Missouri	Used internally to test deployment

Bos taurus	Cow	Missouri	Used internally; new assembly in progress

Cardiocondyla obscurior	Ant, tramp species	Missouri	Community is currently annotating

Monodelphis domestica	Gray, short-tailedopossum	Missouri	Server is available for ongoing annotation

Pogonomyrmex barbatus	Red harvester ant	Missouri	Community is currently annotating

Varroa destructor	Varroa mite	Missouri	Computational gene prediction has begun

Wasmannia auropunctata	Electric ant	Missouri	Community is currently annotating

Pungitius pungitius	Nine spine stickleback	Utahe	Analysis in progress

Over 40 species	Pigeons	Utah	Analysis in progress

Organism

Acanthamoeba castellanii

Helicoverpa armigera

Pythium ultimum

Zea maize

Manduca sexta

Mayetiola destructor

Acromyrmex echinatior

Apis mellifera

Atta cephalotes

Bombus impatiens

Bos taurus

Cardiocondyla obscurior

Monodelphis domestica

Pogonomyrmex barbatus

Varroa destructor

Wasmannia auropunctata

Pungitius pungitius

Over 40 species

Common name	Group	Annotation status

Amoeba	BCM-HGSCa	Server set up in progress

Cotton bollworm	CSIROb	Server set up and analysis in progress

Pythium blight	GMOD	Used one contig to teach a GMOD course

Corn	Iowac	Server set up in progress

Goliath moth	Kansasd	Server set up in progress

Hessian fly	Kansas	Server set up and analysis in progress

Leaf cutting ant	Missouri

Honey bee	LBNL/Missouri	Server is available for ongoing annotation

Leaf cutting ant	Missouri

Eastern bumble bee	Missouri	Used internally to test deployment

Cow	Missouri	Used internally; new assembly in progress

Ant, tramp species	Missouri	Community is currently annotating

Gray, short-tailedopossum	Missouri	Server is available for ongoing annotation

Red harvester ant	Missouri	Community is currently annotating

Varroa mite	Missouri	Computational gene prediction has begun

Electric ant	Missouri	Community is currently annotating

Nine spine stickleback	Utahe	Analysis in progress

Pigeons	Utah	Analysis in progress


Characteristic	Adjusted Odds Ratio (95% Confidence Interval) for Remaining Uninsured for Entire Year

Child uninsured >6 months at baseline	3.8 (1.4, 10.3)

African-American/black race/ethnicitya	2.8 (1.1, 7.3)

Male child gender	2.4 (0.97, 5.8)

Primary caregiver employed	0.5 (0.2, 1.4)

Child born in US	0.2 (0.01, 3.7)

Combined annual family income below federal poverty threshold	0.4 (0.1, 1.4)


	Density (kg/m3)	Thermal conductivity (W/(m °C))	Conductivity (S/m)	Specific heat capacity (J/(kg· °C))

Myocardium	1200	0.55	0.222	3200

Blood	1000	0.543	0.667	4180

Radiofrequency electrode	21,500	71	4,000,000	132

	sity (kg/m3)	 (W/(m °C))	ductivity (S/m)	ific heat capacity (J/(kg· °C))

Myocardium	1200	0.55	0.222	3200

Blood	1000	0.543	0.667	4180

Radiofrequency electrode	21,500	71	4,000,000	132


Diet	ALT	AST

	Euthyroid	Thyroid alt	Euthyroid	Thyroid alt


FGD	Age range at point of FGD	Mean age	No of participants	Male	Female	SCT	CT

FGD 1	13–15	13.5	6	4	2	4	2

FGD 2	15–17	15.7	7	2	5	5	2

FGD 3	19–24	21	7	4	3	2	5

FGD 4	16–20	18	5	2	3	2	3

FGD	Age range at 	Mean 	N	Mal	Female	S	C


Pool code	Region: Site	Elevation (m)	Coordinates	Date	Pool size	Species	Virus detected

T1	Aegean: Canakkale	280	39°29'36.1"N, 26°19'26.7"E	08/2015	20	Cx. theileri	Culex theileri flavivirus

T2	Aegean: Canakkale	280	39°29'36.1"N, 26°19'26.7"E	08/2015	20	Cx. theileri	Culex theileri flavivirus

T3	Thrace: Kirklareli	80	41°36'48.6"N, 26°57'56.3"E	08/2015	43	Cx. theileri	Culex theileri flavivirus

T4	Thrace: Kirklareli	80	41°36'48.3"N, 26°57'56.5"E	11/2014	21	Cx. pipiens (s.l.)	Culex theileri flavivirus

T5	Thrace: Edirne	206	41°48'53.7"N, 26°49'00.7"E	10/2014	1	Ur. unguiculata	Unknown Flavivirus

T6	Thrace: Kirklareli	80	41°36'48.6"N, 26°57'56.3"E	07/2014	52	Ae. caspius	Ochlerotatus caspius flavivirus

T7	Thrace: Kirklareli	120	41°40'23.2"N, 26°58'51.1"E	06/2014	41	Ae. caspius	Ochlerotatus caspius flavivirus

T8	Thrace: Kirklareli	80	41°36'48.3"N, 26°57'56.5"E	10/2014	24	Cx.pipiens (s.l.)	West Nile virus

T9	Thrace: Kirklareli	317	41°36'48.6"N, 26°57'56.3"E	08/2014	7	Cx. theileri	Culex theileri flavivirus

T10	Thrace: Kirklareli	317	41°51'48.3"N, 27°00'59.2"E	08/2014	1	Cx. theileri	Culex theileri flavivirus

T11	Thrace; Kirklareli	112	41°38'12.4"N, 27°10'36.3"E	07/2014	3	Cs. annulata (♂)	Flavivirus AV-2011

Pool code	Region: Site	Elevation (m)	Coordinates	Date	Pool size	Species	Virus detected

T10	Thrace: Kirklareli	317	41°51'48.3"N, 27°00'59.2"E	08/2014	1	Cx. theileri	Culex theileri flavivirus

T11	Thrace; Kirklareli	112	41°38'12.4"N, 27°10'36.3"E	07/2014	3	Cs. annulata (♂)	Flavivirus AV-2011


	Basal Metabolic Rate	Specific Heat	Blood Perfusion Coeff.

	Ao	Cp	B

	[J/(m3 s)]	[J/kg °C]	[J/ (m3 s °C)]

Air	0	1000	0

Blood	0	3640	0

BoneCancellous	590	1300	3300

BoneCortical	610	1300	3400

BrainGreyMatter	7100	3700	40000

BrainWhiteMatter	7100	3600	15925

Cartilage	1600	3500	9000

Cerebellum	7100	3700	40000

CerebroSpinalFluid	0	4200	0

Cornea	0	4200	0

Dura	860	2802	4830

Fat	300	2500	1700

MucousMembrane	1600	3300	9000

Muscle	690	3600	2700

Nerve	7100	3500	40000

Skin Dry	1620	3500	9100

Skin Wet	1620	3500	9100

Tongue*	690	3600	2700

VitreousHumor	0	4200	0


Item	Factor loading	Description	Original item no.	Initial factor	Mean (SD)	ritem-total correlation

1	0.722	Cuando tengo deseos intensos de comer, una vez que empiezo no puedo parar. [When I crave something, I know I won't be able to stop eating once I start]	2	Lack of control	3.01 (1.84)	0.722**

2	0.679	A veces, cuando como lo que se me antoja, pierdo control y como demasiado. [If I eat what I am craving, I often lose control and eat too much]	3	Lack of control	3.86 (1.85)	0.687**

3	0.734	Sin duda alguna, las ganas de comer me hacen pensar cómo voy a conseguirlo [Food cravings invariably make me think of ways to get what I want to eat.]	5	Intentions to eat	2.98 (1.87)	0.735**

4	0.734	No hago más que pensar en la comida. [I feel like I have food on my mind all the time]	6	Food-related thoughts	2.29 (1.56)	0.722**

5	0.650	A veces me encuentro pensativo preocupado con comida. [I find myself preoccupied with food]	8	Food-related thoughts	2.58 (1.73)	0.648**

6	0.679	Cada vez que deseo comer algo en particular me pongo a hacer planes para comer. [Whenever I have cravings, I find myself making plans to eat]	18	Intentions to eat	3.22 (1.89)	0.685**

7	0.623	Siento deseos de comer cuando estoy aburrida, enfadada, o triste. [I crave foods when I feel bored, angry, or sad]	20	Negative affect	3.19 (1.85)	0.634**

8	0.719	No tengo la fuerza de voluntad de resistir mis deseos de comer lo que se me antoja. [I have no will power to resist my food crave]	25	Lack of control	3.54 (1.99)	0.724**

9	0.795	Una vez que me pongo a comer tengo problemas en dejar de comer. [Once I start eating, I have trouble stopping]	26	Lack of control	2.79 (1.87)	0.788**

10	0.783	Por mucho que lo intento, no puedo parar de pensar en comer. [I can't stop thinking about eating no matter how hard I try]	27	Food-related thoughts	2.30 (1.66)	0.771**

11	0.791	Si me dejo llevar por la tentación de comer pierdo todo mi control. [If I give in to a food craving, all control is lost]	29	Lack of control	2.53 (1.85)	0.784**

12	0.784	Cada vez que se me antoja una comida sigo pensando en ella hasta que me la como. [Whenever I have a food craving, I keep on thinking about eating until I actually eat the food]	31	Food-related thoughts	3.08 (1.88)	0.782**

13	0.779	Cuando tengo muchas ganas de comer algo estoy obsesionado con comerlo. [If I am craving something, thoughts of eating it consume me]	32	Food-related thoughts	3.02 (1.86)	0.777**

14	0.633	A menudo deseo comer cuando siento emociones fuertes. [My emotions often make me want to eat]	33	Negative affect	2.72 (1.79)	0.638**

15	0.673	Es difícil resistir la tentación de tomar comidas apetecibles que están a mi alcance. [It is hard for me to resist the temptation to eat appetizing foods that are within reach]	35	Cue-depending eating	3.91 (1.94)	0.683**

Item	Factor loading	Description	Original item no.	Initial factor	Mean (SD)	ritem-total correlation

1	0.722	Cuando tengo deseos intensos de comer, una vez que empiezo no puedo parar. [When I crave something, I know I won't be able to stop eating once I start]	2	Lack of control	3.01 (1.84)	0.722**

2	0.679	A veces, cuando como lo que se me antoja, pierdo control y como demasiado. [If I eat what I am craving, I often lose control and eat too much]	3	Lack of control	3.86 (1.85)	0.687**

		Sin duda alguna, las ganas de comer me hacen pensar cómo voy a	5	Inten	2	0.73

Item	Factor loading	Description	Original item no.	Initial factor	Mean (SD)	ritem-total correlation

3	0.734	 conseguirlo [Food cravings invariably make me think of ways to get what I want to eat.]		tions to eat	.98 (1.87)	5**

4	0.734	No hago más que pensar en la comida. [I feel like I have food on my mind all the time]	6	Food-related thoughts	2.29 (1.56)	0.722**

5	0.650	A veces me encuentro pensativo preocupado con comida. [I find myself preoccupied with food]	8	Food-related thoughts	2.58 (1.73)	0.648**

6	0.679	Cada vez que deseo comer algo en particular me pongo a hacer planes para comer. [Whenever I have cravings, I find myself making plans to eat]	18	Intentions to eat	3.22 (1.89)	0.685**

7	0.623	Siento deseos de comer cuando estoy aburrida, enfadada, o triste. [I crave foods when I feel bored, angry, or sad]	20	Negative affect	3.19 (1.85)	0.634**

8	0.719	No tengo la fuerza de voluntad de resistir mis deseos de comer lo que se me antoja. [I have no will power to resist my food crave]	25	Lack of control	3.54 (1.99)	0.724**

9	0.795	Una vez que me pongo a comer tengo problemas en dejar de comer. [Once I start eating, I have trouble stopping]	26	Lack of control	2.79 (1.87)	0.788**

10	0.783	Por mucho que lo intento, no puedo parar de pensar en comer. [I can't stop thinking about eating no matter how hard I try]	27	Food-related thoughts	2.30 (1.66)	0.771**

11	0.791	Si me dejo llevar por la tentación de comer pierdo todo mi control. [If I give in to a food craving, all control is lost]	29	Lack of control	2.53 (1.85)	0.784**

12	0.784	Cada vez que se me antoja una comida sigo pensando en ella hasta que me la como. [Whenever I have a food craving, I keep on thinking about eating until I actually eat the food]	31	Food-related thoughts	3.08 (1.88)	0.782**

13	0.779	Cuando tengo muchas ganas de comer algo estoy obsesionado con comerlo. [If I am craving something, thoughts of eating it consume me]	32	Food-related thoughts	3.02 (1.86)	0.777**

14	0.633	A menudo deseo comer cuando siento emociones fuertes. [My emotions often make me want to eat]	33	Negative affect	2.72 (1.79)	0.638**

15	0.673	Es difícil resistir la tentación de tomar comidas apetecibles que están a mi alcance. [It is hard for me to resist the temptation to eat appetizing foods that are within reach]	35	Cue-depending eating	3.91 (1.94)	0.683**


	Apixaban	LMWH/VKA/Placebo	Difference	Apixaban	LMWH/VKA	Difference

Number of events(total population)

 Recurrent VTE and VTE-related death	514	577	−62	514	508	6

VTE-related death	63	71	−8	63	63	0

  Recurrent PE	130	146	−16	130	129	1

Recurrent DVT	321	359	−39	321	316	5

 Major bleeds	123	136	−13	123	149	−26

 CRNM bleed	603	631	−28	603	714	−111

 Treatment discontinuation due to adverse events	109	58	51	109	139	−30

Costs

 Anticoagulant costs	£1121	£98	£1023	£1121	£98	£1023

 Monitoring and administration costsa	£63	£261	-£200	£63	£446	-£385

 Event-related costs	£4069	£4214	-£145	£4069	£4170	-£101

QALYs	8.488	8.386	0.101	8.488	8.425	0.063

Life-years	10.421	10.311	0.110	10.421	10.375	0.046

Cost per QALY gained		£6692			£8528

	Apixaban	LMWH/VKA/Placebo	Difference	Apixaban	LMWH/VKA	Difference

Costs

Anticoagulant costs	£1121	£98	£1023	£1121	£98	£1023

Monitoring and administration costsa	£63	£261	-£200	£63	£446	-£385

Event-related costs	£4069	£4214	-£145	£4069	£4170	-£101

QALYs	8.488	8.386	0.101	8.488	8.425	0.063

Life-years	10.421	10.311	0.110	10.421	10.375	0.046

Cost per QALY gained		£6692			£8528


Participants (n)	Age mean (SD)	E-learning interest mean (SD)	E-learning experience mean (SD)


Assay	LK>LK Ri	DH44>LK Ri	DH44>DH44 Ri	LK>DH44 Ri

Effect of manipulation	Global LK knockdown	LK knockdown in ABLKs	Global DH44 knockdown	DH44 knockdown in ABLKs

Desiccation survival	↑****	↑****	No effect	↑****

Starvation survival	↑****	↑****	↑****	↑****

Ionic stress survival	↑****	↑****	↑****	↑****

Chill coma recovery	No effect	↑*	↑*	↑*

Feeding	No effect	No effect	No effect	↓****

Water content	↑**	↑****	No effect	No effect

Assay	LK>LK Ri	DH44>LK Ri

Effect of manipulation	Global LK knockdown	LK knockdown in ABLKs

Desiccation survival	↑****	↑****

Starvation survival	↑****	↑****

Ionic stress survival	↑****	↑****

Chill coma recovery	No effect	↑*

Feeding	No effect	No effect

Water content	↑**	↑****

DH44>DH44 Ri	LK>DH44 Ri

Global DH44 knockdown	DH44 knockdown in ABLKs

No effect	↑****

↑****	↑****

↑****	↑****

↑*	↑*

No effect	↓****

No effect	No effect


	# G

Northwestern European J. communis populations

Cour	9

Heiderbos*	30

Resteigne	24

Cocquerel	18

Grattepanche	32

Hühnermoor	33

Ecksberg	12

Meenser Heide	14

Weinberg	12

Boshuizerbergen	35

Kootwijkerzand	12

Loenen	21

Mantingerzand	34

Flemish J. communis populations

Heiderbos*	57

Kattevennen	26

Hesselberg	26


	TE1 (n = 24)	TE2 (n = 22)	TE3 (n = 30)	TE4 (n = 25)

Condition	D	CN	D	CN

Sex

 Girls	11 (45.8%)	13 (59.1%)	15 (50.0%)	15 (60.0%)

 Boys	13 (54.2%)	9 (40.9%)	15 (50.0%)	10 (40.0%)

Age, mean (SD)	10.58 (0.58)	10.46 (0.67)	10.43 (0.57)	10.48 (0.51)

Race/ethnicity	23 Latino	21 Latino	25 Latino	22 Latino

	1 European American	1 Asian	3 African American	2 African American

			2 Filipino	1 European American

Condition

Sex

Girls

Boys

Age, mean (SD)

Race/ethnicity


Domains	Patients n = 15

Somatisation	0.647 (0.496)

Obsessive-Compulsive	0.670 (0.578)

Interpersonal sensitivity	0.453 (0.504)

Depression	0.753 (0.666)

Anxiety	0.40 (0.417)

Hostility	0.42 (0.581)

Phobic Anxiety	0.11 (0.168)

Paranoid Ideation	0.42 (0.64)

Psychoticism	0.19 (0.292)

Global severity index	0.502 (0.444)

Positive symptom distress index	1.0 (1.73)


Time of assessment	Survival

	1 year	2 years	3 years	5 years

After day 28	33.0%	27.0%	23.9%	19.8%

After ICU discharge (male and female)	61.8%	50.6%	44.7%	37.0%

After ICU discharge (male)	64.7%	53.8%	46.0%	37.7%

After ICU discharge (female)	53.8%	41.6%	41.6%	36.3%

General population (male, age 65 years)a	98.3%	96.5%	94.6%	90.3%

General population (female, age 65 years)a	99.2%	98.4%	97.4%	95.2%


	Antibiotic coated (n=31)	Antibiotic non-coated (n=40)	p

Mean age (years)	48.5	51.2	>0.05

Positive culture n (%)	4 (13)	14 (35)	0.002

Median follow-up (months)	29 (8 to 38)	53 (14 to 82)	<0.05

Mean revision time after first implant (years)	7.1 (2.4 to 8)	9.4 (0.8 to 17)	<0.05


Gene	Gene information	GO term

APOLD1	Apolipoprotein L domain containing 1	Response to abiotic stimulus

ATP13A4	ATPase type 13A4	Transmembrane transport

ATP1A2	ATPase, Na+/K+ transporting, alpha 2 polypeptide	Behavior / response to abiotic stimulus / transmembrane transport

CIART	Circadian associated repressor of transcription	Behavior

GJA1	Gap junction protein, alpha 1, 43 kDa	Behavior / response to abiotic stimulus / transmembrane transport

GPR37	G protein-coupled receptor 37 (endothelin receptor type B-like)	Behavior

HIF3A	Hypoxia inducible factor 3, alpha subunit	Response to abiotic stimulus

IGFBP7	Insulin-like growth factor binding protein 7	Response to abiotic stimulus

MLC1	Megalencephalic leukoencephalopathy with subcortical cysts 1	Response to abiotic stimulus / transmembrane transport

PLOD2	Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2	Response to abiotic stimulus

PREX2	Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2	Behavior

PTN	Pleiotrophin	Behavior

S1PR1	Sphingosine-1-phosphate receptor 1	Behavior

SDC2	Syndecan 2	Response to abiotic stimulus

SDC4	Syndecan 4	Response to abiotic stimulus

SLC14A1	Urea transporter,Kidd blood group	Transmembrane transport

SLC1A2	Glial high affinity glutamate transporter	Behavior / response to abiotic stimulus / transmembrane transport

SLC1A3	Glial high affinity glutamate transporter	Behavior / response to abiotic stimulus / transmembrane transport

SLC4A4	Sodium bicarbonate cotransporter	Transmembrane transport

SLC5A11	Sodium/inositol cotransporter	Transmembrane transport

SLC7A11	Anionic amino acid transporter light chain, xc- system	Transmembrane transport

SLCO1C1	Solute carrier organic anion transporter	Transmembrane transport

TP53BP2	Tumor protein p53 binding protein 2	Response to abiotic stimulus

VEGFA	Vascular endothelial growth factor A	Behavior / response to abiotic stimulus

Gene	Gene information

APOLD1	Apolipoprotein L domain containing 1

ATP13A4	ATPase type 13A4

ATP1A2	ATPase, Na+/K+ transporting, alpha 2 polypeptide

CIART	Circadian associated repressor of transcription

GJA1	Gap junction protein, alpha 1, 43 kDa

GPR37	G protein-coupled receptor 37 (endothelin receptor type B-like)

HIF3A	Hypoxia inducible factor 3, alpha subunit

IGFBP7	Insulin-like growth factor binding protein 7

MLC1	Megalencephalic leukoencephalopathy with subcortical cysts 1

PLOD2	Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2

PREX2	Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2

PTN	Pleiotrophin

S1PR1	Sphingosine-1-phosphate receptor 1

SDC2	Syndecan 2

SDC4	Syndecan 4

SLC14A1	Urea transporter,Kidd blood group

SLC1A2	Glial high affinity glutamate transporter

SLC1A3	Glial high affinity glutamate transporter

SLC4A4	Sodium bicarbonate cotransporter

SLC5A11	Sodium/inositol cotransporter

SLC7A11	Anionic amino acid transporter light chain, xc- system

SLCO1C1	Solute carrier organic anion transporter

TP53BP2	Tumor protein p53 binding protein 2

VEGFA	Vascular endothelial growth factor A

GO term

Response to abiotic stimulus

Transmembrane transport

Behavior / response to abiotic stimulus / transmembrane transport

Behavior

Behavior / response to abiotic stimulus / transmembrane transport

Behavior

Response to abiotic stimulus

Response to abiotic stimulus

Response to abiotic stimulus / transmembrane transport

Response to abiotic stimulus

Behavior

Behavior

Behavior

Response to abiotic stimulus

Response to abiotic stimulus

Transmembrane transport

Behavior / response to abiotic stimulus / transmembrane transport

Behavior / response to abiotic stimulus / transmembrane transport

Transmembrane transport

Transmembrane transport

Transmembrane transport

Transmembrane transport

Response to abiotic stimulus

Behavior / response to abiotic stimulus


Data flow stages

Tool	SQS	Action property	Activity(Yes or No)

Data collection

Primary self-quantification tools	Digifit, BodyTrack and Wikilife	C	Yes

Primary self-quantification tools and apps		U	Yes

Data transmission

Universal Serial Bus (USB) network	Digifit, BodyTrack and Wikilife	S	No

Application has a feature for importing data		U	Yes

Data storing

Files (e.g., XML, CSV, etc.)	Digifit website, BodyTrack and Wikilife	C	Yes

Data aggregation

Connector	Digifit, BodyTrack and Wikilife	S	No

Web-based application		C	Yes

Data visualisation

Web-based application	Digifit website, BodyTrack, and Wikilife	C	Yes

Data sharing

Application has a feature for sharing data with social networks such as Facebook	Digifit website, BodyTrack, and Wikilife	C	Yes

Application has a feature for importing data		C	Yes

Data flow stages

Tool	SQS	Action property	Activity(Yes or No)

Application has a feature for importing data		C	Yes


Pneumococcal serotype	Twofold response to vaccination	Post-vaccination anti-CP† antibody concentration

≥0.35 μg/mL	≥1.00 μg/mL	≥5.00 μg/mL

6B (n = 10)	8	7	3	1

9V (n = 7)	5	7	5	2

19A (n = 1)	0	1	1	0

19F (n = 6)	5	5	3	2

23F (n = 7)	6	6	3	1

Pneumococcal serotype	Twofold response to vaccination	Post-vaccination anti-CP† antibody concentration

≥0.35 μg/mL	≥1.00 μg/mL	≥5.00 μg/mL

19F (n = 6)	5	5	3	2

23F (n = 7)	6	6	3	1


Species	Reads/Contigs	Number	Average size (nt)	Total nt

B. tuediae	Raw reads	547,061	547	299,232,484

	Trimmed reads	546,903	333	182,128,133


Time seizure free after breakthrough seizure (months)	Number at risk	Risk of seizure in following 12 months. %

6	119	32 (28 to 36)

9	99	24 (21 to 27)

12	80	17 (15 to 19)

Time seizure free after breakthrough seizure (months)

6

9

12

Number at risk	Risk of seizure in following 12 months. %

119	32 (28 to 36)

99	24 (21 to 27)

80	17 (15 to 19)


	MZ twins

	Male

Mean age	35.09 (15.27)

Mean HRS	5.85

Mean PADUA	6.99

Tics (prevalence)	192


Cardiac contractility dP/dt (mmHg/sec)

Control	SHR

1622 ± 120	1056 ± 182*


Corpus	Named entity types

GE	Protein

ID	Protein, chemical, organism, Regulon-operon,

 	two-component-system

EPI	Protein

DNAm	Protein

EPTM	Protein

mTOR	Protein, Drug, ion, simple molecule, tag

MLEE	Protein, drug or compound, cellular component, cell, tissue,

 	organ, anatomical system, organism, [ ...]

Corpus	Named entity types

	organ, anatomical system, organism, [ ...]


Health Behaviour	Group	Net change%	Odds Ratio for change	95% CI	NNT#

Fish	Intervention	+7.06	1.37*	1.11-1.64	15

 	Control	+0.84

Spread	Intervention	+5.06	1.28*	1.06-1.51	21

 	Control	+0.37

Salt	Intervention	+5.43	1.19*	1.05-1.38	24

 	Control	+1.23

Veg and fruit	Intervention	+3.14	1.24	0.91-1.68	37

 	Control	+0.49

Meat	Intervention	+7.17	1.16	0.93-1.44	38

 	Control	+4.48

Milk	Intervention	+4.62	1.11	0.96-1.29	45

 	Control	+1.80

Alcohol	Intervention	+3.88	1.16	0.96-1.37	45

 	Control	+1.12

Physical activity	Intervention	+0.48	1.06	0.86-1.30	58

 	Control	−1.34

Body weight	Intervention	−0.12	0.96	0.85-1.09	161

 	Control	−0.82

Smoking	Intervention	+0.24	0.97	0.86-1.12	1000

 	Control	+0.36

Health Behaviour	Group	Net change%	Odds Ratio for change	95% CI	NNT#

Meat	Intervention	+7.17	1.16	0.93-1.44	38

	Control	+4.48

Milk	Intervention	+4.62	1.11	0.96-1.29	45

	Control	+1.80

Alcohol	Intervention	+3.88	1.16	0.96-1.37	45

	Control	+1.12

Physical activity	Intervention	+0.48	1.06	0.86-1.30	58

	Control	−1.34

Body weight	Intervention	−0.12	0.96	0.85-1.09	161

	Control	−0.82

Smoking	Intervention	+0.24	0.97	0.86-1.12	1000

	Control	+0.36


No	Compound name	Area (%)	No	Compound name	Area (%)

1	3-Methyl butanol	0.14	19	β-Phellandrene	0.34

2	Eugenol	1.33	20	α -Thujene	1.26

3	1,8-Cineole	0.24	21	β -Caryophyllene	0.7

4	α -Pinene	0.99	22	γ-Terpinene	2.77

5	Geranyl acetone	0.5	23	Camphene	0.14

6	cis-Sabinene hydrate	0.68	24	α-Franesene	0.7

7	iso-Amylpropionate	0.23	25	Terpinolene	0.22

8	β-Bisabolene	3.77	26	β-Pinene	0.32

9	Linalool	3.32	27	α-Bisabolene	0.51

10	Myrcene	2.43	28	Nonanal	0.24

11	Caryophyllene oxide	1.53	29	trans-2-Carene-4-ol	0.73

12	4-Terpineol	4.1	30	β-Udesmol	0.32

13	iso-Butyl-2-methyl butyrate	0.19	31	α-Terpineol	0.42

14	Heptadecane	0.19	32	3-Carene	0.36

15	Thymyl methyl ether	1.21	33	α-Bisabolol	0.27

16	α-Terpinene	0.73	34	trans-Dihydrocarvone	0.26

17	Musk ambrette	0.08	35	para-Cymene	5.61

18	Carvacrol	63.17


Demographic variables	N	%

Gender	Males	409	55.5

 	Females	328	44.5

Year	First	149	20.2

 	Second	183	24.8

 	Third	152	20.6

 	Fourth	143	19.4

 	Fifth	69	9.3

 	Sixth	41	5.6

Demographic variables	N	%

Gender	Males	409	55.5

	Females	328	44.5

Year	First	149	20.2

	Second	183	24.8

	Third	152	20.6

	Fourth	143	19.4

	Fift	6

Demographic variables	N	%

	h	9	9.3

	Sixth	41	5.6


	UP1	UP2	UPps	SO1	SO2

Number of analysed branches	1,257	14,326	1,298	1,807	13,374


 	Probe	Primer 1	Primer 2

APOA1	CTGCCAGAAATGCCGAGCCTG	CTTTGAGCACATCCACGTACA	GCCGTGCTCTTCCTGAC

APOB	CTGGATACCGTGTATGGAAACTGCTCC	CATTGCCCTTCCTCGTCTT	CCAGAGACAGAAGAAGCCAAG

CPS1	TCCAGCAATCATTCCGGCCAAGA	CCACAGGATTTAAGATACCCCAG	GTAATTGTTCAGCCACACCAAG

CYP1A1	TCTGTGATGTCCCGGATGTGGC	CCCAACCCTTCCCTGAATG	TTCTTCTCCTGACAGTGCTCAATC

FGA	CAGGCAGACGATCCTCATGGAAAACA	CAGCCCCACCCTTAGAAAAG	CTCCTTCAGCTAGAAAGTCACC

FGG	AATAAGGGAGCTAAACAGAGCGGGC	CAAAGACACGGTGCAAATCC	TTCCAGACCCATCGATTTCAC

GSTA1	CGGGCTGACATTCATCTGGTGGA	AAATCGCTACTTCCCTGCC	GGAAGCTGGAGATAAGACTGG

HGD	ATGCAGGCCACTCACAAAGTCTACTT	AGCAAGCCATTGTTAGACTT	CCTGATCCTAACCAGCTTAGATG

HNF1A	CAGGTTGGTGGTGTCGGTGATGA	GCCCTCTACAGCCACAAG	CAGTGTCTGAGGTGAAGACC

HNF4A	CAAGAAATGCTTCCGGGCTGGC	ATAGCTTGACCTTCGAGTGC	TGGACAAAGACAAGAGGAACC

LXR	TGCATAGCTCGTTCCCCAGCATTT	CCCTTCAGAACCCACAGAG	CGCAGCTCAGAACATTGTAGT

RPL13A	AGCAGTACCTGTTTAGCCACGATGG	GCCTTCACAGCGTACGA	CGAAGATGGCGGAGGTG

RXR	AGTACTGCCGCTACCAGAAGTGC	AGGACTGCCTGATTGACAAG	GACTCCACCTCATTCTCGTTC

SERPINA1	TGGTGCCTGAAGCTGAGGAGAC	AGCCAGGGAGACAGGGA	CTTAAATACGGACGAGGACAGG

SLC10A1	AACCTCAGCATTGTGATGACCACCT	TGTACAGGAGGAGAGGCATC	ACCTGTCCAATGTCTTCAGTC

TF	CTGTGTCAACTGTGTCCAGGGTGT	TGAGCCACGTAAACCTCTTG	AGTATTGGTTAAGGGTGGAGC

TTR	AGCAGCCTAGCTCAGGAGAAGTGA	CAGGTTTGCAGTCAGATTGG	CCATCCTGCCAAGAATGAGT

	Probe	Primer 1	Primer 2

RXR	AGTACTGCCGCTACCAGAAGTGC	AGGACTGCCTGATTGACAAG	GACTCCACCTCATTCTCGTTC

SERPINA1	TGGTGCCTGAAGCTGAGGAGAC	AGCCAGGGAGACAGGGA	CTTAAATACGGACGAGGACAGG

SLC10A1	AACCTCAGCATTGTGATGACCACCT	TGTACAGGAGGAGAGGCATC	ACCTGTCCAATGTCTTCAGTC

TF	CTGTGTCAACTGTGTCCAGGGTGT	TGAGCCACGTAAACCTCTTG	AGTATTGGTTAAGGGTGGAGC

TTR	AGCAGCCTAGCTCAGGAGAAGTGA	CAGGTTTGCAGTCAGATTGG	CCATCCTGCCAAGAATGAGT


Pathological target	Putative mechanism	Examples of supporting references	Form of MS most likely to benefit

T- and B-cells	Limit cell proliferation in the periphery and possibly in the CNS	Lederman et al., 1984	RRMS

		Warnke et al., 2009

		Sweeney et al., 2011

Cytokines	Modulate cytokine production in the periphery and possibly in the CNS	Del Vecchio et al., 2002	RRMS

		Weibach et al., 2004

		Leung et al., 2005

Perivascular iron (heme) deposits	Limit iron catalyzed tissue damage to myelin, the BBB, etc.	Wu et al., 1993	RRMS

		Guy et al., 1994

		Nakamura et al., 2004

	Stabilize HIF-1α	Schofield and Ratcliffe, 2005

		Semenza, 2012

		Singh et al., 2012

Demyelination and axonal injury leading to release of iron (or heme) containing products	Limit amplification of tissue damage by iron catalyzed reactions	Wu et al., 1993	RRMS/SPMS

		Kadiiska et al., 1995

		Nakamura et al., 2004

		Merkofer et al., 2006

	Stabilize HIF-1α	Schofield and Ratcliffe, 2005

		Semenza, 2012

		Singh et al., 2012

Activated and iron enriched macrophage, microglia or astrocytes	Limit production of ROS	Rajesh et al., 2004	RRMS/SPMS

	Limit production of proinflammatory cytokines	Molina-Holgado et al., 2008

		Rathnasamy et al., 2011, 2013

	Limit production of MMP-9	Mairuae et al., 2011

	Improve glutamate uptake to lower extracellular levels	Fernandes et al., 2011

Altered mitochondrial function in neurons	Limit ROS production by mitochondria	Richardson et al, 2001	RRMS/SPMS

		Liang et al., 2008

		Im et al., 2012

	Limit caspase-3 activation by mitochondria	Zhang et al., 2009

Enhanced iron deposition in deep gray matter	Limit glutamate excitotoxicity	Papazisis et al., 2008	RRMS/SPMS

		Yu et al., 2009

	Protect against oxidative stress	Molina-Holgado et al., 2008

	Reduce brain iron uptake	Crowe and Morgan, 1994

	Lessen iron induced inhibition of DNA repair machinery	Li et al., 2009

	Stabilize HIF-1α	Schofield and Ratcliffe, 2005

		Semenza, 2012

		Singh et al., 2012

Examples of supporting references

Singh et al., 2012


Anatomical location	Talairach coordinates	Volume (mm3)

	x	y	z

VOCALIZATIONS > ACTION SOUNDS (P < 0.001)

Left aSTG	−58	−4	2	20,069

Left temporal pole	−34	10	−34	31

Right aSTG	54	−4	1	16,801

Right precentral g. (M1)	47	0	48	3303

ACTIONS SOUNDS > VOCALIZATIONS (P < 0.001)

Left Posterior Insula	−36	−28	18	1216

Right Posterior Insula	32	−16	15	761

ACTIONS SOUNDS > VOCALIZATIONS (P < 0.05)

Left MFG	−43	9	32	2848

Left Parietal	−42	−36	31	2011

Left pSTS	−52	−50	3	964

Left aIFS/vlPFC	−45	41	8	4908

Right aIFS/vlPFC	30	29	6	2836

Anatomical location	Talairach coordinates	Volume (mm3)

	x	y	z

ACTIONS SOUNDS > VOCALIZATIONS (P < 0.001)

Left Posterior Insula	−36	−28	18	1216

Right Posterior Insula	32	−16	15	761

ACTIONS SOUNDS > VOCALIZATIONS (P < 0.05)

Left MFG	−43	9	32	2848

Left Parietal	−42	−36	31	2011

Left pSTS	−52	−50	3	964

Left aIFS/vlPFC	−45	41	8	4908

Right aIFS/vlPFC	30	29	6	2836


Treatment	Dose	Analgesic response (mean time in seconds ± SEM)

30 min	60 min

Control (normal saline)	1.0 mL/kg	7.03 ± 0.44	7.34 ± 0.44

E5	1.0 mg/kg	17.66 ± 1.54	19.76 ± 0.26*

E3	1.0 mg/kg	22.51 ± 2.01	25.36 ± 0.21*

Standard (Piroxicam suspension)	1.0 mg/kg	16.95 ± 0.26*	17.41 ± 0.37*


	n	CD8+	CD19+	CD3+	CD4+	NK

Case		2		69.3 ±


Gene with likely pathogenic variant	Steroid-resistant nephrotic syndrome (number of patients)	Haematuria/Alport syndrome (number of patients)

Age group*	≤18 years (n=209)	>18 years (n=46)	Total (n=255)	≤18 years (n=20)	>18 years (n=15)	Total (n=35)

NPHS1	12	0	12	0	0	0

WT1	9	2	11	0	0	0

NPHS2	7	0	7	0	0	0

LMX1B	4	0	4	0	0	0

INF2	0	3	3	0	0	0

LAMB2	3	0	3	0	0	0

MYH9	2	0	2	0	0	0

PLCE1	2	0	2	0	0	0

ACTN4	1	0	1	0	0	0

SCARB2	0	1	1	0	0	0

SMARCAL1	1	0	1	0	0	0

TRPC6	0	1	1	0	0	0

COL4A3	0	1	1	3	2	5

COL4A4	1	1†	2	0	2	2

COL4A5	2	1	3	5	5	10

Total	44	10	54	8	9	17


		Predicted class

Cluster 1	Cluster 2	Cluster 3	Cluster 4

Actual class	Cluster 1	199	49	1	25

Cluster 2	5	441	2	0

Cluster 3	0	0	221	0

Cluster 4	0	0	0	312


Extracted Plant	Extracted Part	IC50 (mg/mL)	Lead Substance	Content (μg/mg)	IC50

Arbutus unedo (strawberry tree)	fruit	n.d. 1	arbutin	20.0 ± 1.3	n.d. 1	n.d. 1

Camellia sinensis (tea)	dried leaves	n.d. 1	caffeine	131.6 ± 5.0	0.9 ± 0.1 mg/mL	4.8 ± 0.6 mM

Cynara scolymus (artichoke)	dried leaves	0.9 ± 0.1	3,4-diCQA	2.5 ± 0.5	>500 μg/mL (49%)	>1.0 mM

luteolin	<0.08	11.8 ± 2.9 μg/mL	41 ± 10 μM

luteolin-7-O-glucuronide	2.7 ± 0.3	n.d. 1	n.d. 1

luteolin-7-O-glucoside	4.9 ± 1.0	n.d. 1	n.d. 1

apigenin	<0.08	n.d. 1	n.d. 1

Zingiber officinale (ginger)	dried rhizome	1.7 ± 0.2	[6]-gingerol	10.0 ± 0.6	>500 μg/mL (38%)	>1.7 mM

lipoid fraction (GLE)	~50	455 ± 19 μg/mL	-

hydrophilic fraction (GWE)	~950	10.5 ± 1.9 mg/mL	-

Cynara scolymus (artichoke)	dried leaves	0.9 ± 0.1	apigenin	<0.08	n.d. 1	n.d. 1

Zingiber officinale (ginger)	dried rhizome	1.7 ± 0.2	[6]-gingerol	10.0 ± 0.6	>500 μg/mL (38%)	>1.7 mM

lipoid fraction (GLE)	~50	455 ± 19 μg/mL	-

hydrophilic fraction (GWE)	~950	10.5 ± 1.9 mg/mL	-


Control sheep (n = 18)	Disease-stressed sheep (n = 10)	Combined groups (n = 10 + 10)

Gene symbol	Stability value (M)	Gene symbol	Stability value (M)	Gene symbol	Stability value (M)

SDHA	0.316	YWHAZ	0.624	SDHA	0.591

YWHAZ	0.342	GAPDH	0.634	YWHAZ	0.593

HPRT	0.344	SDHA	0.667	ACTB	0.596

RPL19	0.361	ACTB	0.701	G6PD	0.666

B2M	0.362	B2M	0.720	GAPDH	0.681

ACTB	0.377	G6PD	0.740	GYPC	0.698

GYPC	0.412	GYPC	0.848	RPL19	0.746

TFRC	0.455	RPL19	1.000	B2M	0.760

G6PD	0.486	HPRT	1.188	HPRT	0.882

PGK1	0.498	PGK1	1.466	TFRC	1.158

GAPDH	0.579	TFRC	1.485	PGK1	1.295


	Guideline	Source

1	Use Dex/sal for MIF (unless documented why not)	NICE

2	Use fluid with 130–154mmol/l sodium for any resus	NICE

3	Receive 0.6-1.4mmol/Kg/day of maintenance sodium	NICE

4	Give <2.5L/day Dex/saline	NICE

5	Patients with Critical Care induced hypernatraemia	Local

	Guideline	Source

2	Use fluid with 130–154mmol/l sodium for any resus	NICE

3	Receive 0.6-1.4mmol/Kg/day of maintenance sodium	NICE

4	Give <2.5L/day Dex/saline	NICE

5	Patients with Critical Care induced hypernatraemia	Local


Parameter	ITS	trnL-F	Combines

Number of accession	49	49	49

Range of sequence length (bp)	642–643	799–801	1442–1443

Characters of data matrix	643	800	1443

Number of constant sites (%)	584 (90.82%)	793 (99.13%)	1377 (96.09%)

Number of parsimony-information sites (%)	55 (8.55%)	7 (0.88%)	62 (4.32%)

Number of autopomorphic-information sites (%)	4 (0.62%)	0 (0.00%)	4 (0.28%)

Consistency index (CI)	0.892	0.969	0.891

Retention index (RI)	0.955	0.958	0.947

Rescaled consistency index (RC)	0.852	0.928	0.844

Homoplasy index (HI)	0.108	0.031	0.109


Hormonal tests	Values (normal range)

Plasmatic cortisol	<39 nmol/L (126.8–656.5)

Plasmatic aldosterone	14.2 pg/mL (18–232)

Plasmatic renin	12.9 μmU/mL (4–50)

Plasmatic noradrenaline	278.2 pg/mL (100–400 lying, 200–700 standing)

Plasmatic adrenaline	15.4 pg/mL (<50 lying, <100 standing)

Plasmatic dopamine	Nondetectable (0–80)

Urinary normetanephrines	289 μg/g creat (46–256)

Urinary metanephrines	98.8 μg/g creat (27–155)

Urinary vanillylmandelic acid	29.1 mg/24 H (1.8–6.7)

Urinary 5-hydroxyindoleacetic acid	6.8 mg/24 H (0.7–8.2)

Hormonal tests	Values (normal range)

Urinary metanephrines	98.8 μg/g creat (27–155)

Urinary vanillylmandelic acid	29.1 mg/24 H (1.8–6.7)

Urinary 5-hydroxyindoleacetic acid	6.8 mg/24 H (0.7–8.2)


GO ID	Molecular Function	Observed Gene Count	FDR

GO.0004702	receptor signaling protein serine/threonine kinase activity	15	3.13E-21

GO.0005515	protein binding	7	2.03E-05

GO.0004708	MAP kinase kinase activity	41	2.41E-05

GO.0017137	Rab GTPase binding	5	2.74E-05

GO.0031489	myosin V binding	6	0.000307

GO.0017022	myosin binding	4	0.000381

GO.0004709	MAP kinase kinase kinase activity	5	0.000518

GO.0005488	binding	4	0.00169

GO.0017075	syntaxin-1 binding	59	0.00354

GO.0004707	MAP kinase activity	3	0.00402

GO.0004674	protein serine/threonine kinase activity	3	0.00636

GO.0004946	bombesin receptor activity	9	0.0113

GO.0005102	receptor binding	2	0.0128

GO.0004908	interleukin-1 receptor activity	14	0.018

GO.0019905	syntaxin binding	2	0.0215

GO.0019899	enzyme binding	4	0.0253

GO.0004871	signal transducer activity	15	0.032

GO.0005179	hormone activity	16	0.0377

GO.0060089	molecular transducer activity	4	0.0377

GO.0086083	cell adhesive protein binding involved in bundle of Hiscell-Purkinje myocyte communication	17	0.0377


Accession NO.	Strain name	Year	Province	Host	Length	Biological sample

KU641013	LN1401	2014	Liaoning	Chicken	2298 bp	Liver

KU645511	LN1402	2014	Liaoning	Chicken	2298 bp	Liver

KU645514	HB1404	2014	Hebei	Chicken	2298 bp	Liver

KU645516	HB1517	2015	Hebei	Chicken	2298 bp	Liver

KU645518	JS1501	2015	Jiangsu	Chicken	2298 bp	Bone marrow

KU645508	JS1502	2015	Jiangsu	Chicken	2298 bp	Bone marrow

KU645509	JS1503	2015	Jiangsu	Chicken	2298 bp	Bone marrow

KU645520	HN1405	2014	Henan	Chicken	2298 bp	Liver

KU645512	HN1504	2015	Henan	Chicken	2298 bp	Liver

KU645517	SD1513	2015	Neimenggu	Chicken	2298 bp	Bone marrow

KU645513	BJ1406	2014	Beijing	Chicken	2298 bp	Bone marrow

KU641014	JN1503	2015	Shandong	Chicken	2298 bp	Bone marrow

KU645523	SD1505	2015	Shandong	Chicken	2298 bp	Liver

KU645507	SD1507	2015	Shandong	Chicken	2298 bp	Liver

KU645519	SD1508	2015	Shandong	Chicken	2298 bp	Bone marrow

KU645510	SD1509	2015	Shandong	Chicken	2298 bp	Bone marrow

KU598851	SD1510	2015	Shandong	Chicken	2298 bp	Bone marrow

KU641015	SD1511	2015	Shandong	Chicken	2298 bp	Liver

KU645506	SD1512	2015	Shandong	Chicken	2298 bp	Liver

KU645521	SD1514	2015	Shandong	Chicken	2298 bp	Liver

KU645515	SD1515	2015	Shandong	Chicken	2298 bp	Liver

KU645522	SD1518	2015	Shandong	Chicken	2298 bp	Liver

KU645524	CAV-Dog	2015	Shandong	Dog	2298 bp	Feces

KU645525	CAV-Mouse	2015	Shandong	Mouse	2298 bp	Feces

Accession NO.	Strain name	Year	Province	Host	Length	Biological sample

KU641			L	Chicken	2298 b	Live

013	LN1401	2014	iaoning		p	r

KU645511	LN1402	2014	Liaoning	Chicken	2298 bp	Liver

KU645514	HB1404	2014	Hebei	Chicken	2298 bp	Liver

KU645516	HB1517	2015	Hebei	Chicken	2298 bp	Liver

KU645518	JS1501	2015	Jiangsu	Chicken	2298 bp	Bone marrow

KU645508	JS1502	2015	Jiangsu	Chicken	2298 bp	Bone marrow

KU645509	JS1503	2015	Jiangsu	Chicken	2298 bp	Bone marrow

KU645520	HN1405	2014	Henan	Chicken	2298 bp	Liver

KU645512	HN1504	2015	Henan	Chicken	2298 bp	Liver

KU645517	SD1513	2015	Neimenggu	Chicken	2298 bp	Bone marrow

KU645513	BJ1406	2014	Beijing	Chicken	2298 bp	Bone marrow

KU641014	JN1503	2015	Shandong	Chicken	2298 bp	Bone marrow

KU645523	SD1505	2015	Shandong	Chicken	2298 bp	Liver

KU645507	SD1507	2015	Shandong	Chicken	2298 bp	Liver

KU645519	SD1508	2015	Shandong	Chicken	2298 bp	Bone marrow

KU645510	SD1509	2015	Shandong	Chicken	2298 bp	Bone marrow

KU598851	SD1510	2015	Shandong	Chicken	2298 bp	Bone marrow

KU641015	SD1511	2015	Shandong	Chicken	2298 bp	Liver

KU645506	SD1512	2015	Shandong	Chicken	2298 bp	Liver

KU645521	SD1514	2015	Shandong	Chicken	2298 bp	Liver

KU645515	SD1515	2015	Shandong	Chicken	2298 bp	Liver

KU645522	SD1518	2015	Shandong	Chicken	2298 bp	Liver

KU645524	CAV-Dog	2015	Shandong	Dog	2298 bp	Feces

KU645525	CAV-Mouse	2015	Shandong	Mouse	2298 bp	Feces


 	No community sports participation	Community sports participation

 	No extracurricular school-based sports participation	Extracurricular school-based sports participation	No extracurricular school-based sports participation	Extracurricular school-based sports participation

 	β (S.E.)	β (S.E.)	β (S.E.)	β (S.E.)

Boys	3.38 (0.10)a	3.97 (0.07)b	4.28 (0.09)c	4.38 (0.04)c

Girls	3.71 (0.08)a#	3.74 (0.07)a#	4.16 (0.07)b	4.28 (0.05)b#


Country	Total number of notified TB cases	TB notification rate per 100 000	Number of notified TB in foreigna	Percentage foreign

Bulgaria	2649	35.0	2	0.1

Estonia	329	24.5	58	17.6

Finland	327	6.1	105	32.1

Greece	489	4.3	231	47.2

Hungary	1741	17.4	21	1.2

Latvia	934	41.5	62	6.6

Lithuania	1938	58.2	47	2.4

Poland	7509	19.7	46	0.6

Romania	21 078	98.2	38	0.2

Slovakia	439	8.1	8	1.8

Total	37 433	35.2	618	1.7


Antibiotic	MIC (μg/ml)

Ampicillin	9.8

Nafcillin	1.25

Ciprofloxacin	25

Nalidixic acid	312

Chloramphenicol	1.25

Minocycline	0.97

Tetracycline	> 50

Erythromycin	> 10

Clindamycin	5

Kanamycin	6

Rifampin	0.4

Metronidazole	0.5

Vancomycin	1.0


State	State Policy Extensiveness*	Geographic Area

California	High	West

Georgia	Middle	Southeast

Illinois	Middle/Low	Midwest

Massachusetts	Low	Northeast (township oriented)

New York	High	Northeast (not township oriented)

Texas	Middle	South Central

State	State Policy Extensiveness*	Geographic Area

Illinois	Middle/Low	Midwest

Massachusetts	Low	Northeast (township oriented)

New York	High	Northeast (not township oriented)

Texas	Middle	South Central


	High worry (Group 1) N = 35	GAD community (Group 2) N = 28	GAD clients (Group 3) N = 32	Panic clients (Group 4) N = 24	F (3, 113)	Partial η2	Post hoc p < .05

Attentional Control Questionnaire	47.73 (8.12)	48.60 (6.65)	42.98 (7.62)	46.02 (7.92)	3.10*	.08	2 > 3


Antigen	Clone	Supplier	Dilution	Antigen retrieval

PR	Mouse Monoclonal, 16	Leica Microsystems	1:100	citrate

ER	Mouse Monoclonal, 6F11	Leica Microsystems	1:100	citrate

Vim	Mouse monoclonal, V9	Leica Microsystems	1:400	citrate

CEA	Mouse monoclonal, 12-140-10	Leica Microsystems	1:100	trypsin

Clone	Supplier	Dilution	Antigen retrieval

Mouse Monoclonal, 16	Leica Microsystems	1:100	citrate

Mouse Monoclonal, 6F11	Leica Microsystems	1:100	citrate

Mouse monoclonal, V9	Leica Microsystems	1:400	citrate

Mouse monoclonal, 12-140-10	Leica Microsystems	1:100	trypsin


Variables	Univentricular	Biventricular	P


Drug	Paw volume increase over time (ml ± SD) and effect (% of negative control)

	1 hr		3 hr		5 hr		7 hr


Condition	SMM and M, number (%)	Maternal deaths

Peritonitis	58(30)	16

Hemorrhage	45(18.7)	10

Hypertensive disease	55(28.6)	9

Cancer	5(1.5)	4

 -pancreatic (1)

 -breast cancer (2)

 -leukemia (1)

Cardiomyopathy	7(3.6)	3

Malaria	6(3)	2

Pulmonary Embolism	2 (2.2)	0

Pulmonary Disease	1 (1.1)	1

Diabetes	2(2.2)

 -severe hypoglycemia,

 -diabetic coma

Hepatic Disease	2(2.2)	0

 -cirrhosis

 -hepatic abscess

Neurologic	2(2.2)

 -stroke postpartum

 -coma of unknown etiology)

Anesthetic complications	2(2.2)

Epilepsy	1 (1.1)	0

Other*	7(3.6)	5

Total number of patients experiencing severe maternal morbidity + mortalitya	192	50

Condition	SMM and M, number (%)	Maternal deaths

Peritonitis	58(30)	16

Hemorrhage	45(18.7)	10

Hypertensi	55(28.6	9

Condition	SMM and M, number (%)	Maternal deaths

ve disease	)

Cancer	5(1.5)	4

-pancreatic (1)

-breast cancer (2)

-leukemia (1)

Cardiomyopathy	7(3.6)	3

Malaria	6(3)	2

Pulmonary Embolism	2 (2.2)	0

Pulmonary Disease	1 (1.1)	1

Diabetes	2(2.2)

-severe hypoglycemia,

-diabetic coma

Hepatic Disease	2(2.2)	0

-cirrhosis

-hepatic abscess

Neurologic	2(2.2)

-stroke postpartum

-coma of unknown etiology)

Anesthetic complications	2(2.2)

Epilepsy	1 (1.1)	0

Other*	7(3.6)	5

Total number of patients experiencing severe maternal morbidity + mortalitya	192	50


Source	1	2	3	4

Farm	A			B		D	E	C	F		G

Health status	SPF			SPF		Non-SPF	SPF	Non-SPF	Non-SPF

Generation	G1	G2	GX	G1	G2	G2	GX	G1	G2	GX	GX

No. pigs:

Performance	47	684	373	92	259	148	300	94	398	72	175

Immune traits	47	0	373	92	68	59	300	94	0	72	175

APP	0	0	373	0	0	0	300	0	0	72	175

No. groups:

Sires	21	42	27	23	5 2,3	5 2,3	17	10	52	11	55

Full-sib families	33	155	200	53	53	53	121	19	53	18	72

Genetic lines	8	4	2	1	1	1	1	1	1	8	13

Breed	LW	LW	LW	LW	LW	LW	LW	LW	LW	LR	LW

Source	1	2	3	4

Farm	A			B		D	E	C	F		G

Health status	SPF			SPF		Non-SPF	SPF	Non-SPF	Non-SPF

APP	0	0	373	0	0	0	300	0	0	72	175

No. groups:

Sires	21	42	27	23	5 2,3	5 2,3	17	10	52	11	55

Full-sib families	33	155	200	53	53	53	121	19	53	18	72

Genetic lines	8	4	2	1	1	1	1	1	1	8	13

Breed	LW	LW	LW	LW	LW	LW	LW	LW	LW	LR	LW


Variables	At the time of enrollment	Follow-up


Variable	Group at the beginning of treatment	Group at the definitive brace removal

Gender	Girls	87 (97%)	Girls	87 (97%)

	Boys	3 (3%)	Boys	3 (3%)

Mean age	Girls	13 years	Girls	15 years 10 months

	Boys	13 years 4 months	Boys	15 years 8 months

Curvative type	Double-major	67 (74.4%)	Double-major	67 (77.0%)

	Lumbar	3 (3.3%)	Lumbar	-

	Thoracic	7 (7.8%)	Thoracic	7 (8.0%)

	Thoraco- lumbar	13 (14.4%)	Thoraco-lumbar	13 (14.9%)

Cobb angle	Double-major	20.9° 20,0°	Double-major	20.6° 16.9°

	Thoracic	20.3°	Thoracic	17.3°

	Thoraco- lumbar	24.1°	Thoraco- lumbar	21.5°

SkeletalMaturity	Risser 0	33 (36.7%)	Achieved

	Risser 1	15 (16.7%)

	Risser 2	21 (23.3%)

	Risser 3	14 (15.6%)

	Risser 4	7 (7.8%)

Theoretical VC	Girls	3.2 litres	Girls	3.6 litres

	Boys	4.1 litres	Boys	4.5 litres

FVC	Girls	2.3 litres	Girls	2.7 litres

	Boys	2.9 litres	Boys	4 litres

Variable	Group at the beginning of treatment	Group at the definitive brace removal

Theoretical VC	Girls	3.2 litres	Girls	3.6 litres

	Boys	4.1 litres	Boys	4.5 litres

FVC	Girls	2.3 litres	Girls	2.7 litres

	Boys	2.9 litres	Boys	4 litres


Gender

Age-groups (3-groups)

Age-groups (5-groups)

RV vaccination

Breastfeeding

Continue with breastfeeding

Number of previous episodes of AGE

Previous hospitalizations for AGE

Attendance at day care center (currently)


Characteristics	Metabolically Normal Obesity n = 114 (%)	Metabolically Abnormal Obesity n = 36 (%)	p-value	p*

Overweight	6 (5)	0 (0)	0.6

Obesity	108 (95)	36 (100)

Systolic blood pressure (mmHg, median, range)	111 (106–121)	133.5 (123.5–138.5)	0.001

Diastolic blood pressure (mmHg, median, range)	70 (66–77)	79.5 (72.5–84.5)	0.06

Waist circumference (cm, median, range)	85 (78–96)	103 (94–109)	< 0.001	< 0.001

Waist-to-height ratio	0.62 [0.58–0.67]	0.66 [0.61–0.69]	0.3


Setting	Level	Type of participants	Type of interviews	Number of interviews

MoH	Principal	Policy makers	Key informant	3

HSB	Principal	Policy makers	Key informant	2

ZACH	Principal	Policy makers	Key informant	1

MEPMO	Principal	Policy makers	Key informant	1

ELB/local clinics	Local/agent	Policy makers	Key informant	3

Local clinics	Local/agent	Sisters in charge/personnel managers	In-depth	7

Local clinics	Local/agent	Healthcare workers	Sample	19

Community	Local/agent	Community members	Focus group discussions (10 people each)	5


 	SLE	HD

Number of cases	103	65

Number of visits (2 or more)	180 (60)	65 (0)

Mean age, years (range)	44 (25–68)	33 (19–59)

Sex, female/male/unknown, n	90/13/0	31/9/24

Race, AA/EA/LA/AsA/IrA/unknown1, n	35/50/12/3/3/0	10/18/6/3/2/25

Race by visit (AA/EA/LA/AsA/IrA/unknown)1, n	64/86/20/7/3/0	10/18/6/3/2/25

Active/inactive by SLEDAI, number of patients	49/131	N/A

Main clinical features, number of patients

Malar rash	9/94	N/A

Discoid lesions	2/101	N/A

Photosensitivity	8/95	N/A

Oral ulcers	7/96	N/A

Arthritis	17/86	N/A

Serositis	4/99	N/A

Pleuritis	5/98	N/A

Nephritis	49/54	N/A

Seizures	2/101	N/A

Psychosis	1/102	N/A


	Wildtype	Mahidolheterozygote	Chinese-4heterozygote	Kaipingheterozygote	Mahidolhomozygote	Mahidol-Canton	Total	Overall allelicfrequency ofall variants	Allelic frequencyof Mahidol variant

Sgaw Karen	91	47	1	1	7	0	147	21.4%	20.7%

Poe Karen	34	12	0	1	4	0	51	20.6%	19.6%

Burman	67	9	1	2	0	1	80	8.8%	6.3%

“Muslim”	11	0	0	0	0	0	11	0.0%	0.0%

Other	6	1	0	0	0	0	7	7.1%	7.1%

“Mixed”	16	5	0	0	0	0	21	11.9%	11.9%

Total	225	74	2	4	11	1	317	16.3%	15.3%


Therapeutic modalities	Frequency (%)

Concomitant radio-chemotherapy	66 (43.7)

Concomitant radio chemotherapy followed by surgery	22 (14.9)

Exclusive radiotherapy	12 (7.9)

Surgery followed by exclusive radiotherapy	25 (16.6)

Surgery followed by concomitant radio chemotherapy	21 (13.9)

Surgery alone	4 (2.6)

Palliative chemotherapy	1 (0.7)

Therapeutic modalities

Concomitant radio-chemotherapy

Concomitant radio chemotherapy followed by surgery

Exclusive radiotherapy

Surgery followed by exclusive radiotherapy

Surgery followed by concomitant radio chemotherapy

Surgery alone

Palliative chemotherapy


Description	Notation	Baseline value	Reference

Population size	N	100,000	assumed

Average life expectancy at birth	1/μ	69.4 (years)	[1]

Transmission coefficient of obesity	β	2.96 × 10-7 (per year)	[12]

Non-contagious hazard of obesity	ε	0.012 (per year)	[13]

Relative hazard of obesity among ex-obese	σ	8.0	[12]

Average duration of obesity	1/γ	35.8 (years)	[13]


	Curative or not	N	Mean	Std. deviation	Std. error mean

Group statistics

 Total HNA score	Curative	3671	26.08	34.312	.566

Not curative	1293	41.13	41.040	1.141

 Number of problems	Curative	3675	5.86	5.460	.090

Not curative	1297	7.64	6.576	.183

 Minutes and seconds for HNA completion	Curative	3675	6 min 56 s	5 min 53 s	6 s

Not curative	1297	8 min 36 s	7 min 5 s	11 s

Total HNA score	Not curative	1293	41.13	41.040	1.141

Number of problems	Curative	3675	5.86	5.460	.090

Not curative	1297	7.64	6.576	.183

Minutes and seconds for HNA completion	Curative	3675	6 min 56 s	5 min 53 s	6 s

Not curative	1297	8 min 36 s	7 min 5 s	11 s


Sample	Litter Concentrations	Application Rates	Analyst

Fe	As	Fe	As

Litter from 2012	2200 ± 252	2.5 ± 3.0	7.41	0.009	This study

Litter from 2014	1106 ± 89	5.2 ± 0.4	3.73	0.013	This study

Sample	Fe	As	Fe	As	Analyst

Litter from 2012	2200 ± 252	2.5 ± 3.0	7.41	0.009	This study

Litter from 2014	1106 ± 89	5.2 ± 0.4	3.73	0.013	This study


Time between onset of symptoms and care at CAMH clinic	n (%)

Within a week	29 (17.5)

More than a week but less than a month	7 (4.2)

1–6 months	50 (30.1)

7–12 months	22 (13.2)

13–24 months	24 (14.5)

25–36 months	14 (8.4)

37–48 months	8 (4.8)

49 months/more	12 (7.2)

Time between onset of symptoms and care at CAMH clinic	n (%)

49 months/more	12 (7.2)


Characteristics	N (%)

Sex

 Male	1087 (53.9%)

 Female	931 (46.1%)

Age (years)

 <3	65 (3.2%)

 3 to <4	294 (14.6%)

 4 to <5	604 (29.9%)

 5 to <6	670 (33.2%)

 ≥6	385 (19.1%)

Residence

 Outlander	765 (37.9%)

 Native	1253 (62.1%)

Town

 Fengjiang	1264 (62.6%)

 Pengjie	754 (37.4%)

Father's education

 Primary school	585 (29.0%)

 Middle and high school	1335 (66.2%)

 College or higher	98 (4.9%)

Father's occupation

 Lead-related	1033 (51.2%)

 Not lead-related	985 (48.8%)

Mother's education

 Primary school	709 (35.1%)

 Middle and high school	1197 (59.3%)

 College or higher	112 (5.6%)

Mother's occupation

 Lead-related	926 (45.9%)

 Not lead-related	1092 (54.1%)

Cares' education

 Primary school	877 (43.5%)

 Middle and high school	1055 (52.3%)

 College or higher	86 (4.3%)

Yearly household income (RMB)

 <10000	679 (33.7%)

 10000–15000	977 (48.4%)

 >15000	362 (17.9%)

Characteristics	N (%)

5 to <6	670 (33.2%)

≥6	385 (19.1%)

Residence

Outlander	765 (37.9%)

Native	1253 (62.1%)

Town

Fengjiang	1264 (62.6%)

Pengjie	754 (37.4%)

Father's education

Primary school	585 (29.0%)

Middle and high school	1335 (66.2%)

College or higher	98 (4.9%)

Father's occupation

Lead-related	1033 (51.2%)

Not lead-related	985 (48.8%)

Mother's education

Primary school	709 (35.1%)

Middle and high school	1197 (59.3%)

College or higher	112 (5.6%)

Mother's occupation

Lead-related	926 (45.9%)

Not lead-related	1092 (54.1%)

Cares' education

Primary school	877 (43.5%)

Middle and high school	1055 (52.3%)

College or higher	86 (4.3%)

Yearly household income (RMB)

<10000	679 (33.7%)

10000–15000	977 (48.4%)

>15000	362 (17.9%)


Item	Concentrate mix (%)	Rye straw (%)	BF-based silage2) (%)

Dry matter	87.9	90.0	58.3

Organic matter	91.7	95.4	88.5

Crude protein	16.4	4.2	16.9

Ether extract	2.5	0.2	3.9

Neutral detergent fiber	32.7	67.7	50.6

Acid detergent fiber	19.5	41.7	38.9

Hemicellulose	13.2	25.9	11.7

Crude fiber	11.3	37.8	31.2

Nitrogen free extracts	61.5	53.3	36.6

Crude ash	8.3	4.6	11.5

Item	Concentrate mix (%)	Rye straw (%)	BF-based silage2) (%)

Ether extract	2.5	0.2	3.9

Neutral detergent fiber	32.7	67.7	50.6

Acid detergent fiber	19.5	41.7	38.9

Hemicellulose	13.2	25.9	11.7

Crude fiber	11.3	37.8	31.2

Nitrogen free extracts	61.5	53.3	36.6

Crude ash	8.3	4.6	11.5


Township	Population Density	Population	Area Percentage of TRs > 10−5	Area Percentage of TRs > 10−4

	(Person/km2)	(Person)	F1	F2	F3	F4	F1	F2	F3	F4

Average	855.23	41,604.64	80.21%	75.12%	76.98%	72.38%	15.60%	13.53%	17.67%	0.57%


Collection time	Pollen viability (%)

A	G	M	Q

05:00–06:00	20.2 ± 1.1a	16.2 ± 1.2a	11.9 ± 2.1a	15.5 ±1.6a


Training Standards in Implant Dentistry, 2016

1	Basic sciences: surgical anatomy, pathological process, bone defects, healing processes

2	Implant science: design and materials, limitations

3	Patient assessment and medical considerations

4	Case assessment and treatment planning: straightforward and complex cases

5	Radiographic assessment and Ionising Radiation Medical Exposure Regulations (IRMER)

6	Communication and informed consent

7	Infection control and asepsis

8	Soft tissue management (raising flaps and suturing)

9	Hard tissue management (autogenous bone augmentation, guided bone regeneration)

10	Pharmacological management

11	Surgical techniques for implant placement procedures

12	Implant-supported restorative procedures

13	Complications and their management

14	Long-term monitoring of implants

15	Record-keeping, documentation and quality assurance


Min–max		(2–5)

Percentile 50 median	4.800


	Cal. Time	mu-prob	mu-prob = 0.2	mu-prob = 0.1	mu-prob = 0.01

Psize

psize = 500	2.63	2.83	2.58


		PPV (%)	Sensitivity (%)

Jitterbug	raw	37.16	89.72

	filtered	92.7	85.05

RetroSeq	extended +/- 100 bp and merged	61.01	90.26

	extended, merged and filtered	87.31	88.21

	PPV (%)	Sensitivity (%)

raw	37.16	89.72

filtered	92.7	85.05

extended +/- 100 bp and merged	61.01	90.26

extended, merged and filtered	87.31	88.21


	eMayo

	Spearman coefficient (R)	p

Disease extension	−0,04	0,687

partial Mayo Score	0,714	<0.001

CRP	0,306	0,004

Leukocytes	0,283	0,007

Haematocrit	−0,237	0,025

Haemoglobin	−0,238	0,024

Thrombocytes	0,175	0,102

Serum Iron	−0,352	0,001

Riley Score	0,724	<0.001

Calprotectin	0,399	0,019

MMP-9	0,505	<0.001


 	n	%	Mean (SD)

Overall satisfactiona	 	 	4.2 (0.77)

Not at all	93	0.9	-

To a small extent	170	1.7	-

To some extent	955	9.5	-

To a large extent	4797	48.0	-

To a very large extent	3987	39.9	-

Benefit of treatmenta	 	 	4.0 (0.92)

No benefit	189	1.9	-

Little benefit	424	4.3	-

Some benefit	1861	18.8	-

Large benefit	4368	44.1	-

Very large benefit	3064	30.9	-

Malpracticea	 	 	4.6 (0.86)

To a very large extent	182	1.8	-

To a large extent	235	2.3	-

To some extent	653	6.4	-

To a small extent	1018	10.0	-

Not at all	8051	79.4	-

Patient-reported experiencesb

Waiting time (elective patients)	4535	-	64.0 (28.8)

Doctor services	10,153	-	73.7 (19.0)

Nursing services	10,245	-	75.4 (17.4)

Information	10,124	-	71.0 (21.0)

Contact with next of kin	7138	-	77.7 (20.8)

Standard	10,199	-	72.6 (17.2)

Organization	10,034	-	68.0 (20.2)

Discharge information	8114	-	58.3 (31.3)

Cooperation with other health services	6071	-	63.8 (29.8)

Sociodemographic variables

Age, years	10,477	 	61.1 (17.9)

Gender, % women	10,477	55.1	-

Self-perceived health

 Excellent	693	7.5	-

 Very good	1,755	19.0	-

 Good	3,139	34.0	-

 Rather good	2,477	26.8	-

 Poor	1,162	12.6	-

Education

Primary school	2,504	27.3	-

 Secondary school	3,560	38.8	-

 University/college < 4 years	2,149	23.4	-

 University/college 4 years or more	974	10.6	-

	n	%	Mean (SD)

xperiencesb

Waiting time (elective patients)	4535	-	64.0 (28.8)

Doctor services	10,153	-	73.7 (19.0)

Nursing services	10,245	-	75.4 (17.4)

Information	10,124	-	71.0 (21.0)

Contact with next of kin	7138	-	77.7 (20.8)

Standard	10,199	-	72.6 (17.2)

Organization	10,034	-	68.0 (20.2)

Discharge information	8114	-	58.3 (31.3)

Cooperation with other health services	6071	-	63.8 (29.8)

Sociodemographic variables

Age, years	10,477		61.1 (17.9)

Gender, % women	10,477	55.1	-

Self-perceived health

Excellent	693	7.5	-

Very good	1,755	19.0	-

Good	3,139	34.0	-

Rather good	2,477	26.8	-

Poor	1,162	12.6	-

Education

Primary school	2,504	27.3	-

Secondary school	3,560	38.8	-

University/college < 4 years	2,149	23.4	-

University/college 4 years or more	974	10.6	-


Models (Prevent/Treatemnt)	Materials	Effect	Dose (Dose-Effect)	Bioactive Compounds	References

Rats treated with ethanol diet (Prevent)	Green tea	↑ Enzymes, non-enzymatic antioxidants; ↓ lipid and protein oxidation	7 g/L in ethanol Lieber-DeCarli diet	Epicatechin, epicatechin gallate	[84]

Rats treated with ethanol (Prevent)	Ziziphus mauritiana leaf	↓ ALT, AST, ALP, total bilirubin, CAT; ↑ GSH-Px, glutathione reductase and SOD	200 and 400 mg/kg b.w. (Dose-effect)	Tannins, saponins and phenolic compounds	[42]

Rats sub-chronically exposed to ethanol (Prevent)	Amaranthus hypochondriacus seed	↓ MDA, NADPH; ↑ Cu, Zn-SOD	140 g/kg in diet	Total phenols	[87]

Mice with acute alcohol-induced liver injury (Prevent)	Peduncles of Hoveniadulcis	↓ ALT, AST, MDA; ↑ SOD, GSH-Px	100, 350 and 600 mg/kg b.w. (Dose-effect)	Non-starch polysaccharide	[86]

Rats treated with ehanol (Prevent)	Methanolic extract from Hammada scoparia leaves	↓ Aminotransferase, glycogen synthase kinase-3 β, lipid peroxidation; ↑ GSH-Px	200 mg/kg b.w.	Phenolic compounds	[85]

Mice with chronic alcoholic liver damage (Prevent)	Jujube honey	↓ Lipoprotein oxidation, AST, ALT, MAD, 8-hydroxy-2-deoxyguanosine; ↑ GSH-Px	27 and 54 g /kg b.w. (Dose-effect)	Phenolic acids	[88]

Mice with alcohol-induced hepatotoxicity (Treatment)	Freeze-dried, germinated and fermented mung bean	↑ Antioxidant levels, NO	200 and 1000 mg/kg b.w.		[89]

Chronic ethanol exposure in rats (Prevent)	Virgin olive oil	↓ Transaminases levels, hepatic lipid peroxidation; ↑ GSH-Px, SOD and CAT	5% (wt/wt) in diet	Tocopherols, chlorophyll, total polyphenols	[90]

Models (Prevent/Treatemnt)	Materials	Effect	Dose (Dose-Effect)	Bioactive Compounds	References

Rats treated with ehanol (Prevent)	Methanolic extract from Hammada scoparia leaves	↓ Aminotransferase, glycogen synthase kinase-3 β, lipid peroxidation; ↑ GSH-Px	200 mg/kg b.w.	Phenolic compounds	[85]

Mice with chronic alcoholic liver damage (Prevent)	Jujube honey	↓ Lipoprotein oxidation, AST, ALT, MAD, 8-hydroxy-2-deoxyguanosine; ↑ GSH-Px	27 and 54 g /kg b.w. (Dose-effect)	Phenolic acids	[88]

Mice with alcohol-induced hepatotoxicity (Treatment)	Freeze-dried, germinated and fermented mung bean	↑ Antioxidant levels, NO	200 and 1000 mg/kg b.w.		[89]

Chronic ethanol exposure in rats (Prevent)	Virgin olive oil	↓ Transaminases levels, hepatic lipid peroxidation; ↑ GSH-Px, SOD and CAT	5% (wt/wt) in diet	Tocopherols, chlorophyll, total polyphenols	[90]


Ethical considerations	Supporting arguments	Opposing arguments	Questions to direct future research

Tobacco harm reduction

 Potential for smoking cessation	E-cigarettes may be as effective as the nicotine patch.	Inconclusive evidence of efficacy for smoking cessation.	What is the efficacy of nicotine and non-nicotine e-cigarettes for smoking cessation and reduction?

Potential for smoking reduction	Demonstrated in multiple studies.	Unlikely that cigarette reduction results in significant health benefits.	What is the long-term impact of dual use of e-cigarettes and tobacco cigarettes on health outcomes?

Product safety

 Potential for long-term adverse effects	Unknown impact of long-term propylene glycol inhalation.	No documented serious adverse events to date.	What are the long-term safety implications of nicotine and non-nicotine e-cigarette use?

Propylene glycol inhalation causes short-term respiratory irritation.

 Autonomy to use a product of unknown risk	Ethical imperative given informed consent.	Public health concerns trump individual rights.	How should consumer rights be weighed against public health concerns?

Use among non-smokers

 Potential to lead to nicotine addiction	Perceived harmlessness may lead never smokers to initiate e-cigarettes.	No evidence for increased nicotine addiction to cause net public health harms.	What is the long-term health impact of nicotine addiction?

 Potential gateway effect	Nicotine acts as a priming agent for the brain.	Unclear implications for transitioning to tobacco cigarettes.	How many non-smokers initiating e-cigarettes transition to other tobacco products, including cigarettes?

Use among youth

 Potential to lead to nicotine addiction	Minors require protection.	No evidence of increased nicotine addiction causing net public health harms.	How many youth initiating e-cigarettes report continuous long-term product use (1 year or longer)?

E-liquid flavorings are attractive to youth.

 Potential gateway effect	Nicotine is a priming agent for the brain.	Unclear implications for transitioning to tobacco cigarettes.	How many youth initiating e-cigarettes transition to other tobacco products, including cigarettes?

 Nicotine poisoning among children	Increased calls to poison control centers.	None.	To what extent can the risk of nicotine poisoning among children be mitigated?

E-liquid flavors are appealing to youth.

Use in public places

 Potential for passive vaping	Stem cell cytotoxicity.	Limited evidence that passive vaping poses significant health concerns.	What is the long-term impact of passive vaping and second-hand vapor exposure?

Aerosolized nicotine emissions.

Renormalized smoking culture

 Potential to subvert decades of anti-smoking efforts	Increased acceptability of smoke-like vapor and smoking behavior.	No evidence that e-cigarettes would be conflated with tobacco cigarettes.	How are the increased awareness and use of e-cigarettes affecting perceptions of cigarette smoking?

Market ownership

 Unethical collaboration with the tobacco industry	Public health endorsement of e-cigarettes increases tobacco company market share.	Possible necessity to collaborate with the tobacco industry to achieve public health gains.	What are the public health implications of tobacco industry ownership of major e-cigarette brands?

Ethical considerations	Supporting arguments	Opposing arguments	Questions to direct future research

Tobacco harm reduction

Potential for smoking cessation	E-cigarettes may be as effective as the nicotine patch.	Inconclusive evidence of efficacy for smoking cessation.	What is the efficacy of nicotine and non-nicotine e-cigarettes for smoking cessation and reduction?

Potential for smoking reduction	Demonstrated in multiple studies.	Unlikely that cigarette reduction results in significant health benefits.	What is the long-term impact of dual use of e-cigarettes and tobacco cigarettes on health outcomes?

Product safety

Potential for long-term adverse effects	Unknown impact of long-term propylene glycol inhalation.	No documented serious adverse events to date.	What are the long-term safety implications of nicotine and non-nicotine e-cigarette use?

Propylene glycol inhalation causes short-term respiratory irritation.

Autonomy to use a product of unknown risk	Ethical imperative given informed consent.	Public health concerns trump individual rights.	How should consumer rights be weighed against public health concerns?

Use among non-smokers

Potential to lead to nicotine addiction	Perceived harmlessness may lead never smokers to initiate e-cigarettes.	No evidence for increased nicotine addiction to cause net public health harms.	What is the long-term health impact of nicotine addiction?

Potential gateway effect	Nicotine acts as a priming agent for the brain.	Unclear implications for transitioning to tobacco cigarettes.	How many non-smokers initiating e-cigarettes transition to other tobacco products, including cigarettes?

Use among youth

Potential to lead to nicotine addiction	Minors require protection.	No evidence of increased nicotine addiction causing net public health harms.	How many youth initiating e-cigarettes report continuous long-term product use (1 year or longer)?

E-liquid flavorings are attractive to youth.

Potential gateway effect	Nicotine is a priming agent for the brain.	Unclear implications for transitioning to tobacco cigarettes.	How many youth initiating e-cigarettes transition to other tobacco products, including cigarettes?

Nicotine poisoning among children	Increased calls to poison control centers.	None.	To what extent can the risk of nicotine poisoning among children be mitigated?

E-liquid flavors are appealing to youth.

Use in public places

Potential for passive va	Stem	Limited evidence that passive vaping pos	What is the

ping	 cell cytotoxicity.	es significant health concerns.	 long-term impact of passive vaping and second-hand vapor exposure?

Aerosolized nicotine emissions.

Renormalized smoking culture

Potential to subvert decades of anti-smoking efforts	Increased acceptability of smoke-like vapor and smoking behavior.	No evidence that e-cigarettes would be conflated with tobacco cigarettes.	How are the increased awareness and use of e-cigarettes affecting perceptions of cigarette smoking?

Market ownership

Unethical collaboration with the tobacco industry	Public health endorsement of e-cigarettes increases tobacco company market share.	Possible necessity to collaborate with the tobacco industry to achieve public health gains.	What are the public health implications of tobacco industry ownership of major e-cigarette brands?


	Lesser illness severity (HoNOS ≥21) (n = 21)	Greater illness severity (HoNOS <21) (n = 26)	P-value ( t-test)

Counts/ day	303697 (194674)	259940 (112820)	0.12 ns

Steps/ day	8563 (3996)	8562 (3237)	0.63 ns

Light activity (mins/day)	197 (42)	214 (48)	0.56 ns

Moderate activity (mins/day)	42 (28)	35 (25)	0.72 ns

Vigorous activity (mins/day)	5 (16)	2 (3)	0.05 ns

Wear time (mins/day)	784 (89)	809 (96)	0.5 ns

Sedentary time (mins/day)	540 (75)	559 (83)	0.65 ns

	Lesser illness severity (HoNOS ≥21) (n = 21)

Counts/ day	303697 (194674)

Steps/ day	8563 (3996)

Light activity (mins/day)	197 (42)

Moderate activity (mins/day)	42 (28)

Vigorous activity (mins/day)	5 (16)

Wear time (mins/day)	784 (89)

Sedentary time (mins/day)	540 (75)


						Genotyped (n)

DPS	Tributary/Region	MPG	# pops	Lineage	Run	Min	Max	Mean	Total

Southwest WA	Columbia Estuary	n/a	4	Coastal	Winter	43	164	85.8	343

Lower Columbia	Clackamas	Cascade	4	Coastal	Mixed	43	92	60.3	241

Lower Columbia	Other	Cascade; Gorge	9	Coastal	Mixed	28	94	68.1	613

Upper Willamette	Willamette	Willamette	3	Coastal	Mixed	39	93	60.7	182

Upper Willamette	Willamette/West Side	Willamette	3	Coastal	Winter	25	30	27.0	81

Middle Columbia	Klickitat	Cascade East Slope	10	Inland	Summer	33	48	43.4	434

Middle Columbia	Deschutes	Cascade East Slope	5	Inland	Summer	31	63	51.4	257

Middle Columbia	John Day	John Day	10	Inland	Summer	18	107	36.3	363

Middle Columbia	Yakima	Yakima	7	Inland	Summer	21	59	36.9	258

Middle Columbia	Other	Mixed	7	Inland	Mixed	34	148	100.1	701

Upper Columbia	Wenatchee	Upper Columbia/East Slope Cascades	6	Inland	Summer	19	99	40.8	245

Upper Columbia	Other	Upper Columbia/East Slope Cascades	5	Inland	Summer	90	99	94.3	475

Snake	Lower Snake	Lower Snake	6	Inland	Summer	49	105	83.5	501

Snake	Lower Clearwater	Clearwater	5	Inland	Summer	49	156	107.8	539

Snake	M. F. Clearwater	Clearwater	14	Inland	Summer	35	99	56.4	789

Snake	S. F. Clearwater	Clearwater	4	Inland	Summer	36	104	57.8	231

Snake	Grande Ronde	Grande Ronde	7	Inland	Summer	45	95	62.7	439

Snake	Imnaha	Imnaha	4	Inland	Summer	23	61	41.5	166

Snake	S. F. Salmon	Salmon	4	Inland	Summer	39	45	43.5	174

Snake	M. F. Salmon	Salmon	8	Inland	Summer	23	84	48.3	386

Snake	Upper Salmon	Salmon	7	Inland	Summer	37	117	83.1	582

Snake	Other Salmon	Salmon	7	Inland	Summer	43	99	55.1	386

Snake	Hatchery	Mixed	6	Inland	Summer	89	146	104.2	625

Total			145						9011

						Genotyped (n)

DPS	Tributary/Region	MPG	# pops	Lineage	Run	Min	Max	Mean	Total

Middle Columbia	Other	Mixed	7	Inland	Mixed	34	148	100.1	701

Upper Columbia	Wenatchee	Upper Columbia/East Slope Cascades	6	Inland	Summer	19	99	40.8	245

Upper Columbia	Other	Upper Columbia/East Slope Cascades	5	Inland	Summer	90	99	94.3	475

Snake	Lower Snake	Lower Snake	6	Inland	Summer	49	105	83.5	501

Snake	Lower Clearwater	Clearwater	5	Inland	Summer	49	156	107.8	539

Snake	M. F. Clearwater	Clearwater	14	Inland	Summer	35	99	56.4	789

Snake	S. F. Clearwater	Clearwater	4	Inland	Summer	36	104	57.8	231

Snake	Grande Ronde	Grande Ronde	7	Inland	Summer	45	95	62.7	439

Snake	Imnaha	Imnaha	4	Inland	Summer	23	61	41.5	166

Snake	S. F. Salmon	Salmon	4	Inland	Summer	39	45	43.5	174

Snake	M. F. Salmon	Salmon	8	Inland	Summer	23	84	48.3	386

Snake	Upper Salmon	Salmon	7	Inland	Summer	37	117	83.1	582

Snake	Other Salmon	Salmon	7	Inland	Summer	43	99	55.1	386

Snake	Hatchery	Mixed	6	Inland	Summer	89	146	104.2	625

Total			145						9011


Factor	Discharged alive (n = 135)	In-hospital death (n = 14)	Hazard Ratio (95% CI)	P-value

n	Summary	n	Summary

Etiology	122		14

Hepatitis		35 (28.7)		7 (50.0)	Reference

Alcoholic liver disease		26 (21.3)		3 (21.4)	0.34 (0.08, 1.4)	0.13

Cryptogenic d		18		2 (14.3)	0.46 (0.0	0.3


		MBS-RK

Shoulder joint angle	RMSE	9.5° (±2.9)

p	0.83

Elbow joint angle	RMSE	11.4° (±2.0)

p	0.97


 	Johnson et al.	Dong et al.

Probe length (nucleotides)	60	60

Median genomic region between probes (nucleotides)	10	153

Number of probes/array	244 000	44 000

Average length of DNA segment hybridized to the array	497	600

Amplification technique	Ligation-Mediated Amplification	Whole Genome Amplification


	Estimates derived by U.S. EPA (2005)	Estimates derived using the Kwon et al. data

Pathway	Mean	50th	75th	95th	99th	Mean	50th	75th	95th	99th

Soil ingestion from deck	0.1	0.0	0.1	0.4	1.3	0.1	0.0	0.1	0.4	0.8

Residue dermal contact from deck	2.2	1.0	2.4	8.0	18.0	0.5	0.5	0.6	0.8	1.0

Soil dermal contact from deck	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.1	0.1


		EmA		TG2-ab (U)

Patient	GFD years	Medium 24 h	PT-gliadin 24 h	PT-gliadin 48 h		Medium 24 h	PT-gliadin 24 h	PT-gliadin 48 h

12	1	neg	neg	neg		2.0	4.8	13.3

13	2	neg	neg	neg		8.8	6.9	4.4

14	4	neg	neg	neg		2.2	6.2	10.3

15	4	neg	neg	neg		2.5	1.7	2.6

16	6	neg	neg	neg		8.1	7.7	12.4

17	7	neg	neg	neg		2.4	3.7	1.9

18	8	neg	neg	neg		2.5	1.3	1.7

19	14	neg	neg	neg		0.9	2.9	0.7

20	20	neg	neg	neg		11.6	2.5	11.6

Median		neg	neg	neg	Median	2.5	3.7	4.4*

		EmA		TG2-ab (U)

Patient	GFD years	Medium 24 h	PT-gliadin 24 h	PT-gliadin 48 h		Medium 24 h	PT-gliadin 24 h	PT-gliadin 48 h

17	7	neg	neg	neg		2.4	3.7	1.9

18	8	neg	neg	neg		2.5	1.3	1.7

19	14	neg	neg	neg		0.9	2.9	0.7

20	20	neg	neg	neg		11.6	2.5	11.6

Median		neg	neg	neg	Median	2.5	3.7	4.4*


Main options	Choices among main options	Ancillary manoeuvres among main option and choices

Loop colostomy (C) (bridge to resection or palliation)

Primary resection with end colostomy: Hartmann’s procedure (HP)

Resection and primary anastomosis (RPA)	Total/subtotal colectomy (TC)	Intraoperative colonic irrigation (ICI)Manual decompression (MD)Covering stoma

Segmental colectomy (SC)

Tube decompression

Endoscopic colonic stenting by self-expanding metallic stents (SEMS)	Bridge to surgery

Palliation

Main options	Choices among main options

Tube decompression

Endoscopic colonic stenting by self-expanding metallic stents (SEMS)	Bridge to surgery

Palliation


Factor	Subgroup	Patients on glargine	Patients on other types of insulin	p-value

(N = 13)	(N = 66)

Breast surgical procedure	Quadrantectomy or lumpectomy Mastectomy	7	23	0.20

6	43

Axillary surgical procedure	Sentinel node biopsy	5	24	0.78

Lymphadenectomy	8	42

Adjuvant Chemotherapy	No	9	50	0.72

Yes	4	16

Adjuvant Hormone therapy	No	3	6	0.17

Yes	10	60

Adjuvant Trastuzumab	No	13	62	1.00

Yes	0	4

Adjuvant Radiotherapy	No	5	32	0.49

Yes	8	34

Outcome	Alive	13	63	1.00

Died of disease	0	3

Breast surgical procedure	Quadrantectomy or lumpectomy Mastectomy	6	43	0.20

Axillary surgical procedure	Sentinel node biopsy	5	24	0.78

Lymphadenectomy	8	42

Adjuvant Chemotherapy	No	9	50	0.72

Yes	4	16

Adjuvant Hormone therapy	No	3	6	0.17

Yes	10	60

Adjuvant Trastuzumab	No	13	62	1.00

Yes	0	4

Adjuvant Radiotherapy	No	5	32	0.49

Yes	8	34

Outcome	Alive	13	63	1.00

Died of disease	0	3


SNP IDHit Orientation	Group	Genotype Frequency	Allele Frequency	Association SignificanceP-value/Odds ratio (95% CI)

rs35069869	Women	AA	AG	GG	A	G

	T1D with	1	153 (0		0.70	0.2


Manufacturer and phantom type	Speed of sound [m/s]	Attenuation [dB/cm/MHz]	Young’s modulus [kPa]

ATS hydrogel-based [25]	1540	n/a	n/a

ATS rubber-based [25]	1440–1460	0.48–0.52	n/a

CIRS hydrogels [26, 27]	1480–1600	0.45–0.75	3–48

Madsen agar with evaporated milk [16]	1541–1543	0.1–0.7	n/a

Hall gelatins [28]	1559–1600	n/a	3–126

King hydrogel-baseda [29]	1539–1583	0.51–0.55	n/a

Our gelatins with evaporated milk:

125-bloom	1532–1574	0.45–0.55	8–11

175-bloom	1536–1566	0.45–0.61	16–22

250-bloom	1543–1563	0.46–0.62	24–34

Manufacturer and phantom type	Speed of sound [m/s]	Attenuation [dB/cm/MHz]	Young’s modulus [kPa]

King hydrogel-baseda [29]	1539–1583	0.51–0.55	n/a

Our gelatins with evaporated milk:

125-bloom	1532–1574	0.45–0.55	8–11

175-bloom	1536–1566	0.45–0.61	16–22

250-bloom	1543–1563	0.46–0.62	24–34


Parameter	Search	Approach	Terminal phase

			F	M	S	L

	4.2 − 8.9	9.8 − 14	13 − 20	13 − 24	13 − 23


	Kawasaki Disease	Febrile Condition

	n = 23 (59.0%)	n = 16 (41.0%)

spanic	)	0%)

Mixed	3 (13.0%)	1 (6.3%)


Outcome	No. of studies	Factor tested	P	Adjusted R2

Total symptom score	9	age	0.296	2.69%

ethnicity	0.254	6.74%

		risk of bias	0.026	49.92%

Severity of inattention	5	age	0.16	54.94%

ethnicity	0.421	−5.75%

		risk of bias	0.345	0.80%

Severity of Hyp-Imp	5	age	0.972	−40.99%

ethnicity	0.257	29.91%

		risk of bias	0.022	100.00%


Characteristic		HR	95% CI	p-value

Age	Per year	0.99	0.96–1.02	0.47

Hormone receptor status	Negative	1 (reference)

	Positive	1.50	0.56–4.06	0.41

HER2 Status	Negative	1 (reference)

	Positive	0.89	0.35–2.25	0.80

Grading	Per grade	1.45	0.70–3.00	0.32

Therapy line	Per line	0.98	0.75–1.26	0.85

CTC count	0	1 (reference)

	≥1	4.20	1.86–9.46	0.001

Characteristic		HR	95% CI	p-value

Age	Per year	0.99	0.96–1.02	0.47

Hormone receptor status	Negative	1 (reference)

	Positive	1.50	0.56–4.06	0.41

HER2 Status	Negative	1 (reference)

	Positive	0.89	0.35–2.25	0.80

Grading	Per grade	1.45	0.70–3.00	0.32

Therapy line	Per line	0.98	0.75–1.26	0.85

CTC count	0	1 (reference)

	≥	4	1.86–9.46	0.0


		DHEA IM group compared to CTR1	DHEA IM group compared to CTR3

Name gene set	# Genes	p-value	FDR	p-value	FDR

DHEA_IM_vs_CTR1_up	98	-	-	0.000*	0.000

DHEA_IM_vs_CTR1_down	208	-	-	0.000*	0.071

DHEA_IM_vs_CTR3_up	46	0.000*	0.000	-	-

DHEA_IM_vs_CTR3_down	19	0.826	0.823	-	-

DHEA_PO_vs_CTR1_up	65	0.000*	0.000	0.751	0.887

DHEA_PO_vs_CTR1_down	73	0.000*	0.000	0.861	0.899

DHEA_P	3		0.07	0.000*


Data process	How and when measured

Frequency of dressing changes in both trial arms	This was calculated from the number of treatment monitoring forms completed by the research nurses indicating a dressing change and included forms completed both prospectively and retrospectively

 	Such data were collected retrospectively when a participant changed location or was self-caring. In such instances, the research nurse would consult patient notes or records kept by the patient to determine the number of dressing changes over a specified period of time

Duration of treatment with allocated trial treatment	Calculated as the difference between the date a patient receiving their allocated treatment to the date they stopped receiving this treatment. This information was available from treatment monitoring forms (as described above)

Reasons for ceasing allocated trial treatment	When, in the clinical judgement of the nurses, a patient could no longer receive their allocated trial treatment, the reason for treatment change was recorded on a treatment monitoring form

Define common adverse events in the study population	All serious and non-serious adverse events that occurred in participants were recorded on adverse events forms. The nature, description and relationship of the event to trial treatment were recorded. The research nurse indicated whether the event was considered to be related to the reference pressure ulcer